$asth 2015 Q3 10-K

Concept	2015 Q3	2015	2014 Q1
Revenue	$11.37M	$32.99M	$2.337M
YoY Change	-2.53%	214.66%	-7.64%
Cost Of Revenue	$8.264M	$22.07M	$2.051M
YoY Change	34.12%	143.13%	2.55%
Gross Profit	$3.105M	$10.92M	$285.6K
YoY Change	-43.58%	675.68%	-42.88%
Gross Profit Margin	27.31%	33.11%	12.22%
Selling, General & Admin	$3.400M	$17.00M	$1.100M
YoY Change	-2.86%	50.44%	0.0%
% of Gross Profit	109.49%	155.64%	385.14%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$77.68K	$334.4K	$5.765K
YoY Change	-59.81%	966.4%	-42.35%
% of Gross Profit	2.5%	3.06%	2.02%
Operating Expenses	$11.78M	$33.68M	$2.884M
YoY Change	20.15%	134.01%	162.14%
Operating Profit	-$412.9K	-$694.3K	-$547.0K
YoY Change	-122.22%	-82.24%	4.18%
Interest Expense	$68.82K	$1.326M	$184.6K
YoY Change	-79.1%	95.29%	-29.01%
% of Operating Profit
Other Income/Expense, Net	-$67.06K	-$489.8K	-$155.8K
YoY Change	-71.53%	-22.19%	310.95%
Pretax Income	-$500.0K	-$1.184M	-$702.8K
YoY Change	-130.81%	-73.91%	-14.6%
Income Tax	-$186.1K	$163.8K	$7.820K
% Of Pretax Income
Net Earnings	-$293.8K	-$1.803M	-$766.4K
YoY Change	-121.35%	-64.09%	-6.87%
Net Earnings / Revenue	-2.58%	-5.46%	-32.8%
Basic Earnings Per Share
Diluted Earnings Per Share	-$102.0K	-$1.788M	-$315.8K
COMMON SHARES
Basic Shares Outstanding	4.863M shares
Diluted Shares Outstanding

Concept	2015 Q3	2015	2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.900M	$9.300M	$13.66M
YoY Change	-53.14%	86.0%	1038.58%
Cash & Equivalents	$3.925M	$9.300M	$6.831M
Short-Term Investments			$6.831M
Other Short-Term Assets	$400.0K	$300.0K	$200.0K
YoY Change	300.0%	-62.5%	100.0%
Inventory
Prepaid Expenses			$53.54K
Receivables	$4.000M	$3.400M	$1.508M
Other Receivables	$300.0K	$600.0K	$0.00
Total Short-Term Assets	$8.700M	$13.60M	$8.406M
YoY Change	-34.88%	37.37%	192.68%
LONG-TERM ASSETS
Property, Plant & Equipment	$600.0K	$1.200M	$94.95K
YoY Change	-3.23%	100.0%	39.34%
Goodwill			$494.7K
YoY Change			1390.06%
Intangibles			$1.377M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.000M	$800.0K	$38.68K
YoY Change	150.0%	-20.0%	24.85%
Total Long-Term Assets	$4.900M	$6.000M	$1.077M
YoY Change	78.78%	17.65%	206.93%
TOTAL ASSETS
Total Short-Term Assets	$8.700M	$13.60M	$8.406M
Total Long-Term Assets	$4.900M	$6.000M	$1.077M
Total Assets	$13.60M	$19.60M	$9.483M
YoY Change	-15.53%	30.67%	194.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.900M	$4.600M	$500.0K
YoY Change	28.95%	39.39%	25.0%
Accrued Expenses			$900.0K
YoY Change			50.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$9.800M	$200.0K	$3.200M
YoY Change	3166.67%	-85.71%	433.33%
Total Short-Term Liabilities	$17.40M	$7.400M	$2.317M
YoY Change	196.08%	23.33%	35.91%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$1.100M
YoY Change	-100.0%	-100.0%	-42.11%
Other Long-Term Liabilities	$0.00	$3.500M	$2.400M
YoY Change	-100.0%	59.09%
Total Long-Term Liabilities	$0.00	$3.500M	$3.500M
YoY Change	-100.0%	-64.65%	84.21%
TOTAL LIABILITIES
Total Short-Term Liabilities	$17.40M	$7.400M	$2.317M
Total Long-Term Liabilities	$0.00	$3.500M	$3.500M
Total Liabilities	$19.30M	$13.80M	$11.11M
YoY Change	16.53%	-22.47%	207.28%
SHAREHOLDERS EQUITY
Retained Earnings			-$17.54M
YoY Change			59.11%
Common Stock			$4.913K
YoY Change			-85.9%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$5.700M	$5.800M	-$2.405M
YoY Change
Total Liabilities & Shareholders Equity	$13.60M	$19.60M	$9.483M
YoY Change	-15.31%	30.67%	194.23%

Concept	2015 Q3	2015	2014 Q1
OPERATING ACTIVITIES
Net Income	-$293.8K	-$1.803M	-$766.4K
YoY Change	-121.35%	-64.09%	-6.87%
Depreciation, Depletion And Amortization	$77.68K	$334.4K	$5.765K
YoY Change	-59.81%	966.4%	-42.35%
Cash From Operating Activities	$200.0K	-$1.840M	-$550.0K
YoY Change	-119.61%	24.48%	175.0%
INVESTING ACTIVITIES
Capital Expenditures	-$40.00K	$44.51K	$12.23K
YoY Change	300.0%	94.1%	-130.57%
Acquisitions		$3.356M	$0.00
YoY Change		1242.46%
Other Investing Activities	$0.00	$20.00K	-$150.0K
YoY Change	-100.0%	-100.63%
Cash From Investing Activities	-$40.00K	-$250.0K	-$160.0K
YoY Change	-98.15%	-8.4%	433.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$500.00	-$2.000M
YoY Change		-100.07%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-120.0K	6.340M	1.150M
YoY Change	-108.7%	212.96%	26.37%
NET CHANGE
Cash From Operating Activities	200.0K	-1.840M	-550.0K
Cash From Investing Activities	-40.00K	-250.0K	-160.0K
Cash From Financing Activities	-120.0K	6.340M	1.150M
Net Change In Cash	40.00K	4.250M	440.0K
YoY Change	-102.22%	1447.25%	-35.29%
FREE CASH FLOW
Cash From Operating Activities	$200.0K	-$1.840M	-$550.0K
Capital Expenditures	-$40.00K	$44.51K	$12.23K
Free Cash Flow	$240.0K	-$1.885M	-$562.2K
YoY Change	-123.76%	25.54%	251.39%

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2015	dei	Entity Registrant Name EntityRegistrantName	Apollo Medical Holdings, Inc.
CY2015	dei	Entity Central Index Key EntityCentralIndexKey	0001083446
CY2015	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2014Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1509589	USD
CY2015Q1	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	208288	USD
CY2015	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2015	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2015	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2014Q3	dei	Entity Public Float EntityPublicFloat	13916424	USD
CY2014Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	41636	USD
CY2015Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	218716	USD
CY2014	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	2976	USD
CY2014Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	USD
CY2015Q1	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	2586854	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6831478	USD
CY2014Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1508461	USD
CY2015Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3801584	USD
CY2014Q1	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	0	USD
CY2014Q1	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	0	USD
CY2015Q1	ameh	Notes And Lines Of Credit Payable Current NotesAndLinesOfCreditPayableCurrent	327141	USD
CY2014Q1	us-gaap	Liabilities Current LiabilitiesCurrent	4551978	USD
CY2014Q1	us-gaap	Liabilities Current LiabilitiesCurrent	2316877	USD
CY2015Q1	us-gaap	Liabilities Current LiabilitiesCurrent	5977712	USD
CY2014Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	5467099	USD
CY2015Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	6234721	USD
CY2014Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	USD
CY2014Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	2354624	USD
CY2014Q1	us-gaap	Due From Affiliate Current DueFromAffiliateCurrent	24041	USD
CY2014Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	53543	USD
CY2014Q1	us-gaap	Assets Current AssetsCurrent	3113944	USD
CY2014Q1	us-gaap	Assets Current AssetsCurrent	8406180	USD
CY2014Q1	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	144345	USD
CY2015Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	582470	USD
CY2014Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	62427	USD
CY2014Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	59627	USD
CY2015Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1377257	USD
CY2014Q1	us-gaap	Goodwill Goodwill	494700	USD
CY2014Q1	us-gaap	Goodwill Goodwill	494700	USD
CY2015Q1	us-gaap	Goodwill Goodwill	2168833	USD
CY2014Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	38681	USD
CY2014Q1	us-gaap	Assets Assets	3959782	USD
CY2014Q1	us-gaap	Assets Assets	9483377	USD
CY2015Q1	us-gaap	Assets Assets	14995063	USD
CY2014Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1087660	USD
CY2014Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1442086	USD
CY2015Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3352204	USD
CY2014Q1	ameh	Medical Liabilities Current MedicalLiabilitiesCurrent	285625	USD
CY2014Q1	ameh	Medical Liabilities Current MedicalLiabilitiesCurrent	552561	USD
CY2015Q1	ameh	Medical Liabilities Current MedicalLiabilitiesCurrent	1260549	USD
CY2014Q1	ameh	Notes And Lines Of Credit Payable Current NotesAndLinesOfCreditPayableCurrent	3178693	USD
CY2014Q1	ameh	Notes And Lines Of Credit Payable Current NotesAndLinesOfCreditPayableCurrent	322230	USD
CY2015Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	2144496	USD
CY2014Q1	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	USD
CY2014Q1	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	4954	USD
CY2015Q1	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	171215	USD
CY2014Q1	us-gaap	Liabilities Liabilities	5652500	USD
CY2014Q1	us-gaap	Liabilities Liabilities	11106532	USD
CY2015Q1	us-gaap	Liabilities Liabilities	15985247	USD
CY2014Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q1	us-gaap	Common Stock Value CommonStockValue	4695	USD
CY2014Q1	us-gaap	Common Stock Value CommonStockValue	4913	USD
CY2015Q1	us-gaap	Common Stock Value CommonStockValue	4863	USD
CY2014Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	14147634	USD
CY2014Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	15127587	USD
CY2015Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	16517985	USD
CY2014Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-16771478	USD
CY2014Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-17537920	USD
CY2015Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-19340521	USD
CY2014Q1	us-gaap	Stockholders Equity StockholdersEquity	-2619149	USD
CY2014Q1	us-gaap	Stockholders Equity StockholdersEquity	-2405420	USD
CY2015Q1	us-gaap	Stockholders Equity StockholdersEquity	-2817673	USD
CY2014Q1	us-gaap	Minority Interest MinorityInterest	926431	USD
CY2014Q1	us-gaap	Minority Interest MinorityInterest	782265	USD
CY2015Q1	us-gaap	Minority Interest MinorityInterest	1827489	USD
CY2014Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1692718	USD
CY2014Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1623155	USD
CY2015Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-990184	USD
CY2014Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3959782	USD
CY2014Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9483377	USD
CY2015Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14995063	USD
CY2015	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	20000	USD
CY2014	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	288601	USD
CY2014Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	167000	USD
CY2015	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	4211231	USD
CY2014	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Business Acquisitions LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions	0	USD
CY2014Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Business Acquisitions LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions	0	USD
CY2015	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Business Acquisitions LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions	458378	USD
CY2014Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	0	USD
CY2015	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	3245283	USD
CY2014	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	0	USD
CY2014Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	0	USD
CY2015	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	90367	USD
CY2014	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	2976	USD
CY2014Q1	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	0	USD
CY2015	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	3335650	USD
CY2014Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2014Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2015Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2014Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4695247	shares
CY2014Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4913455	shares
CY2015Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4863389	shares
CY2014Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4695247	shares
CY2014Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4913455	shares
CY2015Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4863389	shares
CY2014	us-gaap	Revenues Revenues	10484305	USD
CY2014Q1	us-gaap	Revenues Revenues	2336522	USD
CY2015	us-gaap	Revenues Revenues	32989742	USD
CY2014	us-gaap	Cost Of Services CostOfServices	9076213	USD
CY2014Q1	us-gaap	Cost Of Services CostOfServices	2050913	USD
CY2015	us-gaap	Cost Of Services CostOfServices	22067421	USD
CY2014	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5286610	USD
CY2014Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	826870	USD
CY2015	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11282221	USD
CY2014	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	31361	USD
CY2014Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5765	USD
CY2015	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	334434	USD
CY2014	us-gaap	Operating Expenses OperatingExpenses	14394184	USD
CY2014Q1	us-gaap	Operating Expenses OperatingExpenses	2883548	USD
CY2015	us-gaap	Operating Expenses OperatingExpenses	33684076	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-3909879	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-547026	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-694334	USD
CY2014	us-gaap	Interest Expense InterestExpense	679184	USD
CY2014Q1	us-gaap	Interest Expense InterestExpense	184578	USD
CY2015	us-gaap	Interest Expense InterestExpense	1326407	USD
CY2014	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	0	USD
CY2014Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	0	USD
CY2015	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	833545	USD
CY2014	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	49702	USD
CY2014Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	28816	USD
CY2015	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3031	USD
CY2014	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-629482	USD
CY2014Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-155762	USD
CY2015	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-489831	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-4539361	USD
CY2014Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-702788	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1184165	USD
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	19513	USD
CY2014Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7820	USD
CY2014Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2014Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2015Q1	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	1469132	USD
CY2014Q1	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	546078	USD
CY2014Q4	us-gaap	Share Price SharePrice	4.30
CY2014Q4	us-gaap	Share Price SharePrice	4.60
CY2014Q4	us-gaap	Share Price SharePrice	3.90
CY2014Q4	us-gaap	Share Price SharePrice	3.90
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	4.50
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	10.00
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	10.00
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	163792	USD
CY2014	us-gaap	Profit Loss ProfitLoss	-4558874	USD
CY2014Q1	us-gaap	Profit Loss ProfitLoss	-710608	USD
CY2015	us-gaap	Profit Loss ProfitLoss	-1347957	USD
CY2014	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	461424	USD
CY2014Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	55834	USD
CY2015	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	454644	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-5020298	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-766442	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-1802601	USD
CY2015	ameh	Finite Lived Intangible Assets Addition FiniteLivedIntangibleAssetsAddition	1445000	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	5973	USD
CY2014Q1	ameh	Finite Lived Intangible Assets Accumulated Amortization Addition FiniteLivedIntangibleAssetsAccumulatedAmortizationAddition	2800	USD
CY2015	ameh	Finite Lived Intangible Assets Accumulated Amortization Addition FiniteLivedIntangibleAssetsAccumulatedAmortizationAddition	127370	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	8773	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	136143	USD
CY2014Q1	ameh	Finite Lived Intangible Assets Addition Net FiniteLivedIntangibleAssetsAdditionNet	-2800	USD
CY2015	ameh	Finite Lived Intangible Assets Addition Net FiniteLivedIntangibleAssetsAdditionNet	1317630	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	186167	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	185001	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	146537	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	114658	USD
CY2014Q1	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	467636	USD
CY2015Q1	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	1377817	USD
CY2014Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	0	USD
CY2014Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	0	USD
CY2015Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	62000	USD
CY2014Q1	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	452562	USD
CY2014Q1	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	287	USD
CY2014Q1	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	4149	USD
CY2015Q1	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	185051	USD
CY2014Q1	us-gaap	Interest Payable Current InterestPayableCurrent	47722	USD
CY2014Q1	us-gaap	Interest Payable Current InterestPayableCurrent	19780	USD
CY2015Q1	us-gaap	Interest Payable Current InterestPayableCurrent	55529	USD
CY2014Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	119453	USD
CY2014Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	52699	USD
CY2015Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	202675	USD
CY2014Q1	us-gaap	Notes And Loans Payable NotesAndLoansPayable	3178693	USD
CY2014Q1	us-gaap	Notes And Loans Payable NotesAndLoansPayable	5789329	USD
CY2015Q1	us-gaap	Notes And Loans Payable NotesAndLoansPayable	6561862	USD
CY2014Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	1305435	USD
CY2015Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	1060401	USD
CY2014Q1	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	1100522	USD
CY2014Q1	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	962978	USD
CY2015Q1	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	2494921	USD
CY2013Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-391379	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	50936	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	132000	USD
CY2015	us-gaap	Noncontrolling Interest Increase From Sale Of Parent Equity Interest NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest	725278	USD
CY2014Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	60187	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1258848	USD
CY2014Q3	us-gaap	Share Price SharePrice	5.90
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	10.00
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	10.00
CY2014Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P7Y
CY2014Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2014Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2014Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.714	pure
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.637	pure
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.629	pure
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.629	pure
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.621	pure
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.629	pure
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0231	pure
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0163	pure
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0162	pure
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0162	pure
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0147	pure
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0162	pure
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2015	ameh	Price Per Share Level For Future Issuance Of Common Shares PricePerShareLevelForFutureIssuanceOfCommonShares	9.00
CY2014Q1	ameh	Percentage For Down Round Finance PercentageForDownRoundFinance	0.5	pure
CY2014Q1	ameh	Percentage For Liquidated Damages Equal Of Purchase Price PercentageForLiquidatedDamagesEqualOfPurchasePrice	0.0150	pure
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	7500	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1500	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	10000	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	10000	shares
CY2014Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	2.80
CY2014Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	1.70
CY2014Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	1.50
CY2014Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	1.80
CY2014Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	1.50
CY2014Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	101296	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2014Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	10555	shares
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	78519	shares
CY2014Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	0	shares
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	0	shares
CY2014Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	90741	shares
CY2015Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	12222	shares
CY2014	ameh	Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Weighted Average Remaining Vesting Life ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingVestingLife	P1Y6M
CY2014Q1	ameh	Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Weighted Average Remaining Vesting Life ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingVestingLife	P1Y3M18D
CY2015	ameh	Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Weighted Average Remaining Vesting Life ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingVestingLife	P3M18D
CY2014Q1	ameh	Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Grants In Period Weighted Average Remaining Vesting Life ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedGrantsInPeriodWeightedAverageRemainingVestingLife	P0Y
CY2015	ameh	Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Grants In Period Weighted Average Remaining Vesting Life ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedGrantsInPeriodWeightedAverageRemainingVestingLife	P0Y
CY2014Q1	ameh	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Number Of Shares Weighted Average Remaining Vesting Life ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedNumberOfSharesWeightedAverageRemainingVestingLife	P0Y
CY2015	ameh	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Number Of Shares Weighted Average Remaining Vesting Life ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedNumberOfSharesWeightedAverageRemainingVestingLife	P0Y
CY2014Q1	ameh	Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Forfeited Number Of Shares Weighted Average Remaining Vesting Life ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeitedNumberOfSharesWeightedAverageRemainingVestingLife	P0Y
CY2015	ameh	Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Forfeited Number Of Shares Weighted Average Remaining Vesting Life ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeitedNumberOfSharesWeightedAverageRemainingVestingLife	P0Y
CY2014Q1	ameh	Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Weighted Average Per Share Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAveragePerShareIntrinsicValue	0
CY2014Q1	ameh	Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Grants In Period Weighted Average Per Share Instrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedGrantsInPeriodWeightedAveragePerShareInstrinsicValue	0
CY2015	ameh	Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Grants In Period Weighted Average Per Share Instrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedGrantsInPeriodWeightedAveragePerShareInstrinsicValue	0
CY2014Q1	ameh	Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Vested Weighted Average Per Share Instrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedVestedWeightedAveragePerShareInstrinsicValue	0
CY2015	ameh	Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Vested Weighted Average Per Share Instrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedVestedWeightedAveragePerShareInstrinsicValue	0
CY2014Q1	ameh	Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Forfeited Weighted Average Per Share Instrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeitedWeightedAveragePerShareInstrinsicValue	0
CY2015	ameh	Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Forfeited Weighted Average Per Share Instrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeitedWeightedAveragePerShareInstrinsicValue	0
CY2014Q1	ameh	Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Weighted Average Per Share Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAveragePerShareIntrinsicValue	0
CY2015Q1	ameh	Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Weighted Average Per Share Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAveragePerShareIntrinsicValue	0.50
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2014Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0
CY2014Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	4.1
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0
CY2014Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	0
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.69
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	2.2
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y
CY2015	ameh	Share Based Compensation Arrangements By Share Based Payment Award Options Cancelled In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice	0
CY2014Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0
CY2014Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.1
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	0
CY2014Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	0
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	0
CY2014Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	4.1
CY2015Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	4.1
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	735800	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	0	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	162000	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	88767	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	14200	shares
CY2014Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2015	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	0	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	0	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	18333	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	628700	shares
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	776500	shares
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	658306	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.7
CY2014Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	10
CY2014Q1	ameh	Share Based Compensation Arrangements By Share Based Payment Award Options Cancelled In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice	2.3
CY2014Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y8M12D
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y4M24D
CY2014Q1	ameh	Share Based Compensation Arrangement By Share Based Payment Award Options Grant Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm	P0Y
CY2015	ameh	Share Based Compensation Arrangement By Share Based Payment Award Options Grant Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm	P0Y
CY2014Q1	ameh	Share Based Compensation Arrangement By Share Based Payment Award Options Cancellation In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationInPeriodWeightedAverageRemainingContractualTerm	P7Y10M24D
CY2015	ameh	Share Based Compensation Arrangement By Share Based Payment Award Options Cancellation In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationInPeriodWeightedAverageRemainingContractualTerm	P0Y
CY2014Q1	ameh	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm	P0Y
CY2015	ameh	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm	P0Y
CY2014Q1	ameh	Share Based Compensation Arrangement By Share Based Payment Award Options Expired Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm	P0Y
CY2015	ameh	Share Based Compensation Arrangement By Share Based Payment Award Options Expired Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm	P0Y
CY2014Q1	ameh	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageRemainingContractualTerm	P8Y6M
CY2015	ameh	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageRemainingContractualTerm	P0Y
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y1M6D
CY2014Q1	ameh	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageIntrinsicValue	1.60
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue	0
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue	0
CY2014Q1	ameh	Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodTotalIntrinsicValue	0
CY2015	ameh	Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodTotalIntrinsicValue	0
CY2014Q1	ameh	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Per Share Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAveragePerShareIntrinsicValue	0
CY2015	ameh	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Per Share Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAveragePerShareIntrinsicValue	0
CY2014Q1	ameh	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue	0
CY2015	ameh	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue	0
CY2014Q1	ameh	Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodIntrinsicValue	0
CY2015	ameh	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted In Period Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodAggregateIntrinsicValue	0
CY2014Q1	ameh	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Released In Period Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReleasedInPeriodAggregateIntrinsicValue	0
CY2015Q1	ameh	Class Of Warrant Or Right Exercisable ClassOfWarrantOrRightExercisable	414500	shares
CY2015Q1	ameh	Class Of Warrant Or Right Exercisable Weighted Average Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisableWeightedAverageExercisePriceOfWarrantsOrRights	4.60
CY2015	ameh	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Released In Period Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReleasedInPeriodAggregateIntrinsicValue	0
CY2014Q1	ameh	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageFairValue	0.03
CY2015Q1	ameh	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageFairValue	0.07
CY2014	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2157857	USD
CY2014Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	60187	USD
CY2015	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1258848	USD
CY2014Q1	ameh	Class Of Warrant Or Right Outstanding Intrinsic Value ClassOfWarrantOrRightOutstandingIntrinsicValue	0.40
CY2014Q1	ameh	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAggregateIntrinsicValue	0.02
CY2015Q1	ameh	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAggregateIntrinsicValue	0.70
CY2014Q1	ameh	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageFairValue	0.03
CY2014Q1	ameh	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted In Period Weighted Average Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageFairValue	0
CY2015	ameh	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted In Period Weighted Average Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageFairValue	0.77
CY2014Q1	ameh	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Released In Period Weighted Average Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReleasedInPeriodWeightedAverageFairValue	0
CY2015	ameh	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Released In Period Weighted Average Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReleasedInPeriodWeightedAverageFairValue	0
CY2015	ameh	Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodIntrinsicValue	0
CY2014Q1	ameh	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageIntrinsicValue	1.10
CY2015Q1	ameh	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageIntrinsicValue	1.50
CY2015Q1	ameh	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Per Share Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAveragePerShareIntrinsicValue	2.40
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	3752000	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	0	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	184000	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	0	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	183996	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	3752000	shares
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	3752004	shares
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3651675	shares
CY2014	ameh	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term Beginning ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning	P1Y
CY2014Q1	ameh	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term Beginning ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning	P9M18D
CY2015	ameh	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term Beginning ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning	P1M6D
CY2014Q1	ameh	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted	P0Y
CY2015	ameh	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted	P0Y
CY2014Q1	ameh	Sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionequityinstrumentsoutstandingweightedaverageremainingcontractualtermreleased Sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionequityinstrumentsoutstandingweightedaverageremainingcontractualtermreleased	P0Y
CY2015	ameh	Sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionequityinstrumentsoutstandingweightedaverageremainingcontractualtermreleased Sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionequityinstrumentsoutstandingweightedaverageremainingcontractualtermreleased	P0Y
CY2014Q1	ameh	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAggregateIntrinsicValue	0.02
CY2014Q1	ameh	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted In Period Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodAggregateIntrinsicValue	0
CY2014Q1	ameh	Class Of Warrant Or Right Granted Intrinsic Value ClassOfWarrantOrRightGrantedIntrinsicValue	0
CY2015	ameh	Class Of Warrant Or Right Granted Intrinsic Value ClassOfWarrantOrRightGrantedIntrinsicValue	0
CY2014Q1	ameh	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	0
CY2015	ameh	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	0
CY2014Q1	ameh	Class Of Warrant Or Right Cancelled ClassOfWarrantOrRightCancelled	0
CY2015	ameh	Class Of Warrant Or Right Cancelled ClassOfWarrantOrRightCancelled	0
CY2014Q1	ameh	Class Of Warrant Or Right Outstanding Intrinsic Value ClassOfWarrantOrRightOutstandingIntrinsicValue	0.20
CY2014Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	314500	shares
CY2014Q1	ameh	Number Of Warrants Granted NumberOfWarrantsGranted	400000	shares
CY2015	ameh	Number Of Warrants Granted NumberOfWarrantsGranted	200000	shares
CY2014Q1	ameh	Number Of Warrants Exercised NumberOfWarrantsExercised	0	shares
CY2015	ameh	Number Of Warrants Exercised NumberOfWarrantsExercised	0	shares
CY2014Q1	ameh	Class Of Warrant Or Right Cancelled In Period ClassOfWarrantOrRightCancelledInPeriod	0	shares
CY2015	ameh	Class Of Warrant Or Right Cancelled In Period ClassOfWarrantOrRightCancelledInPeriod	0	shares
CY2014Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	714500	shares
CY2015Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	914500	shares
CY2015	ameh	Class Of Warrant Or Right Issued In Period ClassOfWarrantOrRightIssuedInPeriod	914500	shares
CY2015	ameh	Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm	P4Y3M18D
CY2014	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2014Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	4954	USD
CY2015	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-51922	USD
CY2014	us-gaap	Adjustment For Amortization AdjustmentForAmortization	255396	USD
CY2014Q1	us-gaap	Adjustment For Amortization AdjustmentForAmortization	25965	USD
CY2015	us-gaap	Adjustment For Amortization AdjustmentForAmortization	121578	USD
CY2014	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	136751	USD
CY2014Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	19406	USD
CY2015	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	400394	USD
CY2014	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-72916	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1128	USD
CY2015	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	912205	USD
CY2014	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	0	USD
CY2014Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	0	USD
CY2015	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	188236	USD
CY2014	us-gaap	Increase Decrease Due From Affiliates IncreaseDecreaseDueFromAffiliates	-4049	USD
CY2014Q1	us-gaap	Increase Decrease Due From Affiliates IncreaseDecreaseDueFromAffiliates	22442	USD
CY2015	us-gaap	Increase Decrease Due From Affiliates IncreaseDecreaseDueFromAffiliates	-55358	USD
CY2014	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-19084	USD
CY2014Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-11342	USD
CY2015	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	118054	USD
CY2014	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	27700	USD
CY2014Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	2952	USD
CY2015	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	106510	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	455738	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	621360	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	851277	USD
CY2014	ameh	Increase Decrease In Medical Liabilities IncreaseDecreaseInMedicalLiabilities	0	USD
CY2014Q1	ameh	Increase Decrease In Medical Liabilities IncreaseDecreaseInMedicalLiabilities	0	USD
CY2015	ameh	Increase Decrease In Medical Liabilities IncreaseDecreaseInMedicalLiabilities	249610	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-1478205	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-8895	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-271910	USD
CY2014	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	250000	USD
CY2014Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2015	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	3356145	USD
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	22931	USD
CY2014Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	12228	USD
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	44509	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-272931	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-12228	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-3200375	USD
CY2014	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	220000	USD
CY2014Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2015	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	2000000	USD
CY2014	ameh	Principal Payments On Term Note Payable PrincipalPaymentsOnTermNotePayable	530000	USD
CY2014Q1	ameh	Principal Payments On Term Note Payable PrincipalPaymentsOnTermNotePayable	0	USD
CY2015	ameh	Principal Payments On Term Note Payable PrincipalPaymentsOnTermNotePayable	936083	USD
CY2014	us-gaap	Proceeds From Payments To Minority Shareholders ProceedsFromPaymentsToMinorityShareholders	0	USD
CY2014Q1	us-gaap	Proceeds From Payments To Minority Shareholders ProceedsFromPaymentsToMinorityShareholders	0	USD
CY2015	us-gaap	Proceeds From Payments To Minority Shareholders ProceedsFromPaymentsToMinorityShareholders	725278	USD
CY2014	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	240000	USD
CY2014Q1	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	200000	USD
CY2015	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	600000	USD
CY2014	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	730000	USD
CY2014Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2000000	USD
CY2015	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2014	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	258151	USD
CY2014Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	232676	USD
CY2015	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	533646	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	40894	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	673257	USD
CY2015	ameh	Warrants To Purchase Common Stock WarrantsToPurchaseCommonStock	30000	shares
CY2015	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	2400	USD
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.16
CY2015	dei	Trading Symbol TradingSymbol	AMEH
CY2015Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	4863389	shares
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	2025816	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	5401194	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	1655049	USD
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	274680	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	5380071	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-1817236	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1176727	USD
CY2014	us-gaap	Interest Paid InterestPaid	247465	USD
CY2014Q1	us-gaap	Interest Paid InterestPaid	84720	USD
CY2015	us-gaap	Interest Paid InterestPaid	768845	USD
CY2014	us-gaap	Income Taxes Paid IncomeTaxesPaid	19513	USD
CY2014Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	3824	USD
CY2015	us-gaap	Income Taxes Paid IncomeTaxesPaid	32197	USD
CY2014	ameh	Convertible Note Warrant ConvertibleNoteWarrant	50936	USD
CY2014Q1	ameh	Convertible Note Warrant ConvertibleNoteWarrant	0	USD
CY2015	ameh	Convertible Note Warrant ConvertibleNoteWarrant	487620	USD
CY2014	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	0	USD
CY2014Q1	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	0	USD
CY2015	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	578155	USD
CY2014	us-gaap	Other Significant Noncash Transaction Value Of Consideration Given1 OtherSignificantNoncashTransactionValueOfConsiderationGiven1	0	USD
CY2014Q1	us-gaap	Other Significant Noncash Transaction Value Of Consideration Given1 OtherSignificantNoncashTransactionValueOfConsiderationGiven1	0	USD
CY2015	us-gaap	Other Significant Noncash Transaction Value Of Consideration Given1 OtherSignificantNoncashTransactionValueOfConsiderationGiven1	132000	USD
CY2015Q1	ameh	Common Stock Issuable Upon Conversion Of Convertible Nine Senior Notes CommonStockIssuableUponConversionOfConvertibleNineSeniorNotes	275000	shares
CY2015Q1	ameh	Common Stock Issuable Upon Conversion Of Convertible Eight Senior Notes CommonStockIssuableUponConversionOfConvertibleEightSeniorNotes	200000	shares
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	90000	shares
CY2014	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	660893	USD
CY2014Q1	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	660893	USD
CY2015	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	660893	USD
CY2014	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.37
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.37
CY2014	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	3666165	shares
CY2014Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	4717521	shares
CY2015	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	4891652	shares

CY2015

dei

Current Fiscal Year End Date

CurrentFiscalYearEndDate

--03-31

CY2015

dei

Entity Registrant Name

EntityRegistrantName

Apollo Medical Holdings, Inc.

CY2015

dei

Entity Central Index Key

EntityCentralIndexKey

0001083446

CY2015

dei

Entity Well Known Seasoned Issuer

EntityWellKnownSeasonedIssuer

No

CY2014Q1

us-gaap

Accounts Receivable Net Current

AccountsReceivableNetCurrent

1509589

USD

CY2015Q1

us-gaap

Accounts And Other Receivables Net Current

AccountsAndOtherReceivablesNetCurrent

208288

USD

CY2015

dei

Entity Filer Category

EntityFilerCategory

Smaller Reporting Company

CY2015

dei

Entity Current Reporting Status

EntityCurrentReportingStatus

Yes

CY2015

dei

Entity Voluntary Filers

EntityVoluntaryFilers

No

CY2014Q3

dei

Entity Public Float

EntityPublicFloat

13916424

USD

CY2014Q1

us-gaap

Other Assets Noncurrent

OtherAssetsNoncurrent

41636

USD

CY2015Q1

us-gaap

Other Assets Noncurrent

OtherAssetsNoncurrent

218716

USD

CY2014

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1

2976

USD

CY2014Q1

us-gaap

Long Term Notes Payable

LongTermNotesPayable

0

USD

CY2015Q1

us-gaap

Financial Liabilities Fair Value Disclosure

FinancialLiabilitiesFairValueDisclosure

2586854

USD

CY2014Q1

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

6831478

USD

CY2014Q1

us-gaap

Accounts Receivable Net Current

AccountsReceivableNetCurrent

1508461

USD

CY2015Q1

us-gaap

Accounts Receivable Net Current

AccountsReceivableNetCurrent

3801584

USD

CY2014Q1

us-gaap

Accounts And Other Receivables Net Current

AccountsAndOtherReceivablesNetCurrent

0

USD

CY2014Q1

us-gaap

Accounts And Other Receivables Net Current

AccountsAndOtherReceivablesNetCurrent

0

USD

CY2015Q1

ameh

Notes And Lines Of Credit Payable Current

NotesAndLinesOfCreditPayableCurrent

327141

USD

CY2014Q1

us-gaap

Liabilities Current

LiabilitiesCurrent

4551978

USD

CY2014Q1

us-gaap

Liabilities Current

LiabilitiesCurrent

2316877

USD

CY2015Q1

us-gaap

Liabilities Current

LiabilitiesCurrent

5977712

USD

CY2014Q1

us-gaap

Long Term Notes Payable

LongTermNotesPayable

5467099

USD

CY2015Q1

us-gaap

Long Term Notes Payable

LongTermNotesPayable

6234721

USD

CY2014Q1

us-gaap

Derivative Liabilities Noncurrent

DerivativeLiabilitiesNoncurrent

0

USD

CY2014Q1

us-gaap

Derivative Liabilities Noncurrent

DerivativeLiabilitiesNoncurrent

2354624

USD

CY2014Q1

us-gaap

Due From Affiliate Current

DueFromAffiliateCurrent

24041

USD

CY2014Q1

us-gaap

Prepaid Expense Current

PrepaidExpenseCurrent

53543

USD

CY2014Q1

us-gaap

Assets Current

AssetsCurrent

3113944

USD

CY2014Q1

us-gaap

Assets Current

AssetsCurrent

8406180

USD

CY2014Q1

us-gaap

Deferred Finance Costs Noncurrent Net

DeferredFinanceCostsNoncurrentNet

144345

USD

CY2015Q1

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

582470

USD

CY2014Q1

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

62427

USD

CY2014Q1

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

59627

USD

CY2015Q1

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

1377257

USD

CY2014Q1

us-gaap

Goodwill

494700

USD

CY2014Q1

us-gaap

Goodwill

494700

USD

CY2015Q1

us-gaap

Goodwill

2168833

USD

CY2014Q1

us-gaap

Other Assets Noncurrent

OtherAssetsNoncurrent

38681

USD

CY2014Q1

us-gaap

Assets

3959782

USD

CY2014Q1

us-gaap

Assets

9483377

USD

CY2015Q1

us-gaap

Assets

14995063

USD

CY2014Q1

us-gaap

Accounts Payable And Accrued Liabilities Current

AccountsPayableAndAccruedLiabilitiesCurrent

1087660

USD

CY2014Q1

us-gaap

Accounts Payable And Accrued Liabilities Current

AccountsPayableAndAccruedLiabilitiesCurrent

1442086

USD

CY2015Q1

us-gaap

Accounts Payable And Accrued Liabilities Current

AccountsPayableAndAccruedLiabilitiesCurrent

3352204

USD

CY2014Q1

ameh

Medical Liabilities Current

MedicalLiabilitiesCurrent

285625

USD

CY2014Q1

ameh

Medical Liabilities Current

MedicalLiabilitiesCurrent

552561

USD

CY2015Q1

ameh

Medical Liabilities Current

MedicalLiabilitiesCurrent

1260549

USD

CY2014Q1

ameh

Notes And Lines Of Credit Payable Current

NotesAndLinesOfCreditPayableCurrent

3178693

USD

CY2014Q1

ameh

Notes And Lines Of Credit Payable Current

NotesAndLinesOfCreditPayableCurrent

322230

USD

CY2015Q1

us-gaap

Derivative Liabilities Noncurrent

DerivativeLiabilitiesNoncurrent

2144496

USD

CY2014Q1

us-gaap

Deferred Tax Liabilities

DeferredTaxLiabilities

0

USD

CY2014Q1

us-gaap

Deferred Tax Liabilities

DeferredTaxLiabilities

4954

USD

CY2015Q1

us-gaap

Deferred Tax Liabilities

DeferredTaxLiabilities

171215

USD

CY2014Q1

us-gaap

Liabilities

5652500

USD

CY2014Q1

us-gaap

Liabilities

11106532

USD

CY2015Q1

us-gaap

Liabilities

15985247

USD

CY2014Q1

us-gaap

Commitments And Contingencies

CommitmentsAndContingencies

USD

CY2014Q1

us-gaap

Commitments And Contingencies

CommitmentsAndContingencies

USD

CY2015Q1

us-gaap

Commitments And Contingencies

CommitmentsAndContingencies

USD

CY2014Q1

us-gaap

Preferred Stock Value

PreferredStockValue

0

USD

CY2014Q1

us-gaap

Preferred Stock Value

PreferredStockValue

0

USD

CY2015Q1

us-gaap

Preferred Stock Value

PreferredStockValue

0

USD

CY2014Q1

us-gaap

Common Stock Value

CommonStockValue

4695

USD

CY2014Q1

us-gaap

Common Stock Value

CommonStockValue

4913

USD

CY2015Q1

us-gaap

Common Stock Value

CommonStockValue

4863

USD

CY2014Q1

us-gaap

Additional Paid In Capital

AdditionalPaidInCapital

14147634

USD

CY2014Q1

us-gaap

Additional Paid In Capital

AdditionalPaidInCapital

15127587

USD

CY2015Q1

us-gaap

Additional Paid In Capital

AdditionalPaidInCapital

16517985

USD

CY2014Q1

us-gaap

Retained Earnings Accumulated Deficit

RetainedEarningsAccumulatedDeficit

-16771478

USD

CY2014Q1

us-gaap

Retained Earnings Accumulated Deficit

RetainedEarningsAccumulatedDeficit

-17537920

USD

CY2015Q1

us-gaap

Retained Earnings Accumulated Deficit

RetainedEarningsAccumulatedDeficit

-19340521

USD

CY2014Q1

us-gaap

Stockholders Equity

StockholdersEquity

-2619149

USD

CY2014Q1

us-gaap

Stockholders Equity

StockholdersEquity

-2405420

USD

CY2015Q1

us-gaap

Stockholders Equity

StockholdersEquity

-2817673

USD

CY2014Q1

us-gaap

Minority Interest

MinorityInterest

926431

USD

CY2014Q1

us-gaap

Minority Interest

MinorityInterest

782265

USD

CY2015Q1

us-gaap

Minority Interest

MinorityInterest

1827489

USD

CY2014Q1

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

-1692718

USD

CY2014Q1

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

-1623155

USD

CY2015Q1

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

-990184

USD

CY2014Q1

us-gaap

Liabilities And Stockholders Equity

LiabilitiesAndStockholdersEquity

3959782

USD

CY2014Q1

us-gaap

Liabilities And Stockholders Equity

LiabilitiesAndStockholdersEquity

9483377

USD

CY2015Q1

us-gaap

Liabilities And Stockholders Equity

LiabilitiesAndStockholdersEquity

14995063

USD

CY2015

us-gaap

Health Care Organization Patient Service Revenue

HealthCareOrganizationPatientServiceRevenue

20000

USD

CY2014

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense

288601

USD

CY2014Q1

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense

167000

USD

CY2015

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense

4211231

USD

CY2014

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Business Acquisitions

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions

0

USD

CY2014Q1

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Business Acquisitions

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions

0

USD

CY2015

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Business Acquisitions

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions

458378

USD

CY2014Q1

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1

0

USD

CY2015

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1

3245283

USD

CY2014

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1

0

USD

CY2014Q1

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1

0

USD

CY2015

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1

90367

USD

CY2014

us-gaap

Payments For Losses And Loss Adjustment Expense

PaymentsForLossesAndLossAdjustmentExpense

2976

USD

CY2014Q1

us-gaap

Payments For Losses And Loss Adjustment Expense

PaymentsForLossesAndLossAdjustmentExpense

0

USD

CY2015

us-gaap

Payments For Losses And Loss Adjustment Expense

PaymentsForLossesAndLossAdjustmentExpense

3335650

USD

CY2014Q1

us-gaap

Preferred Stock Par Or Stated Value Per Share

PreferredStockParOrStatedValuePerShare

0.001

CY2014Q1

us-gaap

Preferred Stock Par Or Stated Value Per Share

PreferredStockParOrStatedValuePerShare

0.001

CY2015Q1

us-gaap

Preferred Stock Par Or Stated Value Per Share

PreferredStockParOrStatedValuePerShare

0.001

CY2014Q1

us-gaap

Preferred Stock Shares Authorized

PreferredStockSharesAuthorized

5000000

shares

CY2014Q1

us-gaap

Preferred Stock Shares Authorized

PreferredStockSharesAuthorized

5000000

shares

CY2015Q1

us-gaap

Preferred Stock Shares Authorized

PreferredStockSharesAuthorized

5000000

shares

CY2014Q1

us-gaap

Preferred Stock Shares Issued

PreferredStockSharesIssued

0

shares

CY2014Q1

us-gaap

Preferred Stock Shares Issued

PreferredStockSharesIssued

0

shares

CY2015Q1

us-gaap

Preferred Stock Shares Issued

PreferredStockSharesIssued

0

shares

CY2014Q1

us-gaap

Common Stock Par Or Stated Value Per Share

CommonStockParOrStatedValuePerShare

0.001

CY2014Q1

us-gaap

Common Stock Par Or Stated Value Per Share

CommonStockParOrStatedValuePerShare

0.001

CY2015Q1

us-gaap

Common Stock Par Or Stated Value Per Share

CommonStockParOrStatedValuePerShare

0.001

CY2014Q1

us-gaap

Common Stock Shares Authorized

CommonStockSharesAuthorized

100000000

shares

CY2014Q1

us-gaap

Common Stock Shares Authorized

CommonStockSharesAuthorized

100000000

shares

CY2015Q1

us-gaap

Common Stock Shares Authorized

CommonStockSharesAuthorized

100000000

shares

CY2014Q1

us-gaap

Common Stock Shares Issued

CommonStockSharesIssued

4695247

shares

CY2014Q1

us-gaap

Common Stock Shares Issued

CommonStockSharesIssued

4913455

shares

CY2015Q1

us-gaap

Common Stock Shares Issued

CommonStockSharesIssued

4863389

shares

CY2014Q1

us-gaap

Common Stock Shares Outstanding

CommonStockSharesOutstanding

4695247

shares

CY2014Q1

us-gaap

Common Stock Shares Outstanding

CommonStockSharesOutstanding

4913455

shares

CY2015Q1

us-gaap

Common Stock Shares Outstanding

CommonStockSharesOutstanding

4863389

shares

CY2014

us-gaap

Revenues

10484305

USD

CY2014Q1

us-gaap

Revenues

2336522

USD

CY2015

us-gaap

Revenues

32989742

USD

CY2014

us-gaap

Cost Of Services

CostOfServices

9076213

USD

CY2014Q1

us-gaap

Cost Of Services

CostOfServices

2050913

USD

CY2015

us-gaap

Cost Of Services

CostOfServices

22067421

USD

CY2014

us-gaap

General And Administrative Expense

GeneralAndAdministrativeExpense

5286610

USD

CY2014Q1

us-gaap

General And Administrative Expense

GeneralAndAdministrativeExpense

826870

USD

CY2015

us-gaap

General And Administrative Expense

GeneralAndAdministrativeExpense

11282221

USD

CY2014

us-gaap

Depreciation Depletion And Amortization

DepreciationDepletionAndAmortization

31361

USD

CY2014Q1

us-gaap

Depreciation Depletion And Amortization

DepreciationDepletionAndAmortization

5765

USD

CY2015

us-gaap

Depreciation Depletion And Amortization

DepreciationDepletionAndAmortization

334434

USD

CY2014

us-gaap

Operating Expenses

OperatingExpenses

14394184

USD

CY2014Q1

us-gaap

Operating Expenses

OperatingExpenses

2883548

USD

CY2015

us-gaap

Operating Expenses

OperatingExpenses

33684076

USD

CY2014

us-gaap

Operating Income Loss

OperatingIncomeLoss

-3909879

USD

CY2014Q1

us-gaap

Operating Income Loss

OperatingIncomeLoss

-547026

USD

CY2015

us-gaap

Operating Income Loss

OperatingIncomeLoss

-694334

USD

CY2014

us-gaap

Interest Expense

InterestExpense

679184

USD

CY2014Q1

us-gaap

Interest Expense

InterestExpense

184578

USD

CY2015

us-gaap

Interest Expense

InterestExpense

1326407

USD

CY2014

us-gaap

Gain Loss On Derivative Instruments Net Pretax

GainLossOnDerivativeInstrumentsNetPretax

0

USD

CY2014Q1

us-gaap

Gain Loss On Derivative Instruments Net Pretax

GainLossOnDerivativeInstrumentsNetPretax

0

USD

CY2015

us-gaap

Gain Loss On Derivative Instruments Net Pretax

GainLossOnDerivativeInstrumentsNetPretax

833545

USD

CY2014

us-gaap

Other Nonoperating Income Expense

OtherNonoperatingIncomeExpense

49702

USD

CY2014Q1

us-gaap

Other Nonoperating Income Expense

OtherNonoperatingIncomeExpense

28816

USD

CY2015

us-gaap

Other Nonoperating Income Expense

OtherNonoperatingIncomeExpense

3031

USD

CY2014

us-gaap

Nonoperating Income Expense

NonoperatingIncomeExpense

-629482

USD

CY2014Q1

us-gaap

Nonoperating Income Expense

NonoperatingIncomeExpense

-155762

USD

CY2015

us-gaap

Nonoperating Income Expense

NonoperatingIncomeExpense

-489831

USD

CY2014

us-gaap

Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments

IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

-4539361

USD

CY2014Q1

us-gaap

Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments

IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

-702788

USD

CY2015

us-gaap

Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments

IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

-1184165

USD

CY2014

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

19513

USD

CY2014Q1

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

7820

USD

CY2014Q3

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

P6Y

CY2014Q4

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

P6Y

CY2015Q1

us-gaap

Workers Compensation Liability Current

WorkersCompensationLiabilityCurrent

1469132

USD

CY2014Q1

us-gaap

Workers Compensation Liability Current

WorkersCompensationLiabilityCurrent

546078

USD

CY2014Q4

us-gaap

Share Price

SharePrice

4.30

CY2014Q4

us-gaap

Share Price

SharePrice

4.60

CY2014Q4

us-gaap

Share Price

SharePrice

3.90

CY2014Q4

us-gaap

Share Price

SharePrice

3.90

CY2014Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice

4.50

CY2014Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice

10.00

CY2014Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice

10.00

CY2015

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

163792

USD

CY2014

us-gaap

Profit Loss

ProfitLoss

-4558874

USD

CY2014Q1

us-gaap

Profit Loss

ProfitLoss

-710608

USD

CY2015

us-gaap

Profit Loss

ProfitLoss

-1347957

USD

CY2014

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

461424

USD

CY2014Q1

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

55834

USD

CY2015

us-gaap

Net Income Loss Attributable To Noncontrolling Interest

NetIncomeLossAttributableToNoncontrollingInterest

454644

USD

CY2014

us-gaap

Net Income Loss

NetIncomeLoss

-5020298

USD

CY2014Q1

us-gaap

Net Income Loss

NetIncomeLoss

-766442

USD

CY2015

us-gaap

Net Income Loss

NetIncomeLoss

-1802601

USD

CY2015

ameh

Finite Lived Intangible Assets Addition

FiniteLivedIntangibleAssetsAddition

1445000

USD

CY2014Q1

us-gaap

Finite Lived Intangible Assets Accumulated Amortization

FiniteLivedIntangibleAssetsAccumulatedAmortization

5973

USD

CY2014Q1

ameh

Finite Lived Intangible Assets Accumulated Amortization Addition

FiniteLivedIntangibleAssetsAccumulatedAmortizationAddition

2800

USD

CY2015

ameh

Finite Lived Intangible Assets Accumulated Amortization Addition

FiniteLivedIntangibleAssetsAccumulatedAmortizationAddition

127370

USD

CY2014Q1

us-gaap

Finite Lived Intangible Assets Accumulated Amortization

FiniteLivedIntangibleAssetsAccumulatedAmortization

8773

USD

CY2015Q1

us-gaap

Finite Lived Intangible Assets Accumulated Amortization

FiniteLivedIntangibleAssetsAccumulatedAmortization

136143

USD

CY2014Q1

ameh

Finite Lived Intangible Assets Addition Net

FiniteLivedIntangibleAssetsAdditionNet

-2800

USD

CY2015

ameh

Finite Lived Intangible Assets Addition Net

FiniteLivedIntangibleAssetsAdditionNet

1317630

USD

CY2015Q1

us-gaap

Finite Lived Intangible Assets Amortization Expense Next Twelve Months

FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths

186167

USD

CY2015Q1

us-gaap

Finite Lived Intangible Assets Amortization Expense Year Two

FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo

185001

USD

CY2015Q1

us-gaap

Finite Lived Intangible Assets Amortization Expense Year Three

FiniteLivedIntangibleAssetsAmortizationExpenseYearThree

146537

USD

CY2015Q1

us-gaap

Finite Lived Intangible Assets Amortization Expense Year Four

FiniteLivedIntangibleAssetsAmortizationExpenseYearFour

114658

USD

CY2014Q1

us-gaap

Accounts Payable Current And Noncurrent

AccountsPayableCurrentAndNoncurrent

467636

USD

CY2015Q1

us-gaap

Accounts Payable Current And Noncurrent

AccountsPayableCurrentAndNoncurrent

1377817

USD

CY2014Q1

us-gaap

Other Accrued Liabilities Current

OtherAccruedLiabilitiesCurrent

0

USD

CY2014Q1

us-gaap

Other Accrued Liabilities Current

OtherAccruedLiabilitiesCurrent

0

USD

CY2015Q1

us-gaap

Other Accrued Liabilities Current

OtherAccruedLiabilitiesCurrent

62000

USD

CY2014Q1

us-gaap

Workers Compensation Liability Current

WorkersCompensationLiabilityCurrent

452562

USD

CY2014Q1

us-gaap

Accrued Income Taxes

AccruedIncomeTaxes

287

USD

CY2014Q1

us-gaap

Accrued Income Taxes

AccruedIncomeTaxes

4149

USD

CY2015Q1

us-gaap

Accrued Income Taxes

AccruedIncomeTaxes

185051

USD

CY2014Q1

us-gaap

Interest Payable Current

InterestPayableCurrent

47722

USD

CY2014Q1

us-gaap

Interest Payable Current

InterestPayableCurrent

19780

USD

CY2015Q1

us-gaap

Interest Payable Current

InterestPayableCurrent

55529

USD

CY2014Q1

us-gaap

Accrued Professional Fees Current

AccruedProfessionalFeesCurrent

119453

USD

CY2014Q1

us-gaap

Accrued Professional Fees Current

AccruedProfessionalFeesCurrent

52699

USD

CY2015Q1

us-gaap

Accrued Professional Fees Current

AccruedProfessionalFeesCurrent

202675

USD

CY2014Q1

us-gaap

Notes And Loans Payable

NotesAndLoansPayable

3178693

USD

CY2014Q1

us-gaap

Notes And Loans Payable

NotesAndLoansPayable

5789329

USD

CY2015Q1

us-gaap

Notes And Loans Payable

NotesAndLoansPayable

6561862

USD

CY2014Q1

us-gaap

Debt Instrument Unamortized Discount

DebtInstrumentUnamortizedDiscount

1305435

USD

CY2015Q1

us-gaap

Debt Instrument Unamortized Discount

DebtInstrumentUnamortizedDiscount

1060401

USD

CY2014Q1

us-gaap

Convertible Notes Payable

ConvertibleNotesPayable

1100522

USD

CY2014Q1

us-gaap

Convertible Notes Payable

ConvertibleNotesPayable

962978

USD

CY2015Q1

us-gaap

Convertible Notes Payable

ConvertibleNotesPayable

2494921

USD

CY2013Q1

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

-391379

USD

CY2014

us-gaap

Adjustments To Additional Paid In Capital Warrant Issued

AdjustmentsToAdditionalPaidInCapitalWarrantIssued

50936

USD

CY2015

us-gaap

Adjustments To Additional Paid In Capital Warrant Issued

AdjustmentsToAdditionalPaidInCapitalWarrantIssued

132000

USD

CY2015

us-gaap

Noncontrolling Interest Increase From Sale Of Parent Equity Interest

NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest

725278

USD

CY2014Q1

us-gaap

Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value

AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

60187

USD

CY2015

us-gaap

Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value

AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

1258848

USD

CY2014Q3

us-gaap

Share Price

SharePrice

5.90

CY2014Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice

10.00

CY2014Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice

10.00

CY2014Q1

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

P7Y

CY2014Q4

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

P6Y

CY2014Q4

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

P6Y

CY2014Q4

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

P6Y

CY2014Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

0.714

pure

CY2014Q3

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

0.637

pure

CY2014Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

0.629

pure

CY2014Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

0.629

pure

CY2014Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

0.621

pure

CY2014Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

0.629

pure

CY2014Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

0.0231

pure

CY2014Q3

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

0.0163

pure

CY2014Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

0.0162

pure

CY2014Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

0.0162

pure

CY2014Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

0.0147

pure

CY2014Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

0.0162

pure

CY2014Q3

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

0

pure

CY2014Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

0

pure

CY2014Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

0

pure

CY2014Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

0

pure

CY2014Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

0

pure

CY2015

ameh

Price Per Share Level For Future Issuance Of Common Shares

PricePerShareLevelForFutureIssuanceOfCommonShares

9.00

CY2014Q1

ameh

Percentage For Down Round Finance

PercentageForDownRoundFinance

0.5

pure

CY2014Q1

ameh

Percentage For Liquidated Damages Equal Of Purchase Price

PercentageForLiquidatedDamagesEqualOfPurchasePrice

0.0150

pure

CY2014Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

7500

shares

CY2014Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

1500

shares

CY2014Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

10000

shares

CY2014Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

10000

shares

CY2014Q3

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue

2.80

CY2014Q4

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue

1.70

CY2014Q4

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue

1.50

CY2014Q4

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue

1.80

CY2014Q4

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue

1.50

CY2014Q1

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares

101296

shares

CY2014Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

0

shares

CY2015

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

0

shares

CY2014Q1

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares

10555

shares

CY2015

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares

78519

shares

CY2014Q1

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares

0

shares

CY2015

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares

0

shares

CY2014Q1

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares

90741

shares

CY2015Q1

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares

12222

shares

CY2014

ameh

Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Weighted Average Remaining Vesting Life

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingVestingLife

P1Y6M

CY2014Q1

ameh

Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Weighted Average Remaining Vesting Life

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingVestingLife

P1Y3M18D

CY2015

ameh

Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Weighted Average Remaining Vesting Life

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingVestingLife

P3M18D

CY2014Q1

ameh

Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Grants In Period Weighted Average Remaining Vesting Life

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedGrantsInPeriodWeightedAverageRemainingVestingLife

P0Y

CY2015

ameh

Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Grants In Period Weighted Average Remaining Vesting Life

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedGrantsInPeriodWeightedAverageRemainingVestingLife

P0Y

CY2014Q1

ameh

Share Based Compensation Arrangement By Share Based Payment Award Options Vested Number Of Shares Weighted Average Remaining Vesting Life

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedNumberOfSharesWeightedAverageRemainingVestingLife

P0Y

CY2015

ameh

Share Based Compensation Arrangement By Share Based Payment Award Options Vested Number Of Shares Weighted Average Remaining Vesting Life

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedNumberOfSharesWeightedAverageRemainingVestingLife

P0Y

CY2014Q1

ameh

Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Forfeited Number Of Shares Weighted Average Remaining Vesting Life

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeitedNumberOfSharesWeightedAverageRemainingVestingLife

P0Y

CY2015

ameh

Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Forfeited Number Of Shares Weighted Average Remaining Vesting Life

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeitedNumberOfSharesWeightedAverageRemainingVestingLife

P0Y

CY2014Q1

ameh

Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Weighted Average Per Share Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAveragePerShareIntrinsicValue

0

CY2014Q1

ameh

Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Grants In Period Weighted Average Per Share Instrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedGrantsInPeriodWeightedAveragePerShareInstrinsicValue

0

CY2015

ameh

Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Grants In Period Weighted Average Per Share Instrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedGrantsInPeriodWeightedAveragePerShareInstrinsicValue

0

CY2014Q1

ameh

Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Vested Weighted Average Per Share Instrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedVestedWeightedAveragePerShareInstrinsicValue

0

CY2015

ameh

Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Vested Weighted Average Per Share Instrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedVestedWeightedAveragePerShareInstrinsicValue

0

CY2014Q1

ameh

Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Forfeited Weighted Average Per Share Instrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeitedWeightedAveragePerShareInstrinsicValue

0

CY2015

ameh

Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Forfeited Weighted Average Per Share Instrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedForfeitedWeightedAveragePerShareInstrinsicValue

0

CY2014Q1

ameh

Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Weighted Average Per Share Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAveragePerShareIntrinsicValue

0

CY2015Q1

ameh

Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Weighted Average Per Share Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAveragePerShareIntrinsicValue

0.50

CY2015

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

0

CY2014Q1

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice

0

CY2014Q1

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue

4.1

CY2014Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

0

CY2015

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

0

CY2014Q1

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue

0

CY2015

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice

0

CY2014Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

2

CY2015Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

4.69

CY2015Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice

2.2

CY2014

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

P9Y

CY2015

ameh

Share Based Compensation Arrangements By Share Based Payment Award Options Cancelled In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice

0

CY2014Q1

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

0

CY2015

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice

0

CY2014Q1

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice

2.1

CY2015

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue

0

CY2014Q1

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue

0

CY2015

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue

0

CY2014Q1

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue

4.1

CY2015Q1

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue

4.1

CY2014Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

735800

shares

CY2014Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod

0

shares

CY2015

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod

162000

shares

CY2014Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod

88767

shares

CY2015

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod

14200

shares

CY2014Q1

us-gaap

Stock Issued During Period Shares Stock Options Exercised

StockIssuedDuringPeriodSharesStockOptionsExercised

0

shares

CY2015

us-gaap

Stock Issued During Period Shares Stock Options Exercised

StockIssuedDuringPeriodSharesStockOptionsExercised

0

shares

CY2014Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod

0

shares

CY2015

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod

0

shares

CY2014Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

18333

shares

CY2015

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

0

shares

CY2014Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

628700

shares

CY2015Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

776500

shares

CY2015Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

658306

shares

CY2014Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

1.7

CY2014Q1

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

0

CY2015

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

10

CY2014Q1

ameh

Share Based Compensation Arrangements By Share Based Payment Award Options Cancelled In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice

2.3

CY2014Q1

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

P8Y8M12D

CY2015

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

P7Y4M24D

CY2014Q1

ameh

Share Based Compensation Arrangement By Share Based Payment Award Options Grant Weighted Average Remaining Contractual Term

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm

P0Y

CY2015

ameh

Share Based Compensation Arrangement By Share Based Payment Award Options Grant Weighted Average Remaining Contractual Term

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm

P0Y

CY2014Q1

ameh

Share Based Compensation Arrangement By Share Based Payment Award Options Cancellation In Period Weighted Average Remaining Contractual Term

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationInPeriodWeightedAverageRemainingContractualTerm

P7Y10M24D

CY2015

ameh

Share Based Compensation Arrangement By Share Based Payment Award Options Cancellation In Period Weighted Average Remaining Contractual Term

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancellationInPeriodWeightedAverageRemainingContractualTerm

P0Y

CY2014Q1

ameh

Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Remaining Contractual Term

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm

P0Y

CY2015

ameh

Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Remaining Contractual Term

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm

P0Y

CY2014Q1

ameh

Share Based Compensation Arrangement By Share Based Payment Award Options Expired Weighted Average Remaining Contractual Term

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm

P0Y

CY2015

ameh

Share Based Compensation Arrangement By Share Based Payment Award Options Expired Weighted Average Remaining Contractual Term

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm

P0Y

CY2014Q1

ameh

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Weighted Average Remaining Contractual Term

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageRemainingContractualTerm

P8Y6M

CY2015

ameh

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Weighted Average Remaining Contractual Term

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageRemainingContractualTerm

P0Y

CY2015

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1

P5Y1M6D

CY2014Q1

ameh

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageIntrinsicValue

1.60

CY2014Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue

0

CY2015

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue

0

CY2014Q1

ameh

Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period Total Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodTotalIntrinsicValue

0

CY2015

ameh

Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period Total Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodTotalIntrinsicValue

0

CY2014Q1

ameh

Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Per Share Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAveragePerShareIntrinsicValue

0

CY2015

ameh

Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Per Share Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAveragePerShareIntrinsicValue

0

CY2014Q1

ameh

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue

0

CY2015

ameh

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue

0

CY2014Q1

ameh

Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodIntrinsicValue

0

CY2015

ameh

Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted In Period Aggregate Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodAggregateIntrinsicValue

0

CY2014Q1

ameh

Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Released In Period Aggregate Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReleasedInPeriodAggregateIntrinsicValue

0

CY2015Q1

ameh

Class Of Warrant Or Right Exercisable

ClassOfWarrantOrRightExercisable

414500

shares

CY2015Q1

ameh

Class Of Warrant Or Right Exercisable Weighted Average Exercise Price Of Warrants Or Rights

ClassOfWarrantOrRightExercisableWeightedAverageExercisePriceOfWarrantsOrRights

4.60

CY2015

ameh

Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Released In Period Aggregate Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReleasedInPeriodAggregateIntrinsicValue

0

CY2014Q1

ameh

Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageFairValue

0.03

CY2015Q1

ameh

Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageFairValue

0.07

CY2014

us-gaap

Allocated Share Based Compensation Expense

AllocatedShareBasedCompensationExpense

2157857

USD

CY2014Q1

us-gaap

Allocated Share Based Compensation Expense

AllocatedShareBasedCompensationExpense

60187

USD

CY2015

us-gaap

Allocated Share Based Compensation Expense

AllocatedShareBasedCompensationExpense

1258848

USD

CY2014Q1

ameh

Class Of Warrant Or Right Outstanding Intrinsic Value

ClassOfWarrantOrRightOutstandingIntrinsicValue

0.40

CY2014Q1

ameh

Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Aggregate Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAggregateIntrinsicValue

0.02

CY2015Q1

ameh

Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Aggregate Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAggregateIntrinsicValue

0.70

CY2014Q1

ameh

Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageFairValue

0.03

CY2014Q1

ameh

Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted In Period Weighted Average Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageFairValue

0

CY2015

ameh

Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted In Period Weighted Average Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageFairValue

0.77

CY2014Q1

ameh

Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Released In Period Weighted Average Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReleasedInPeriodWeightedAverageFairValue

0

CY2015

ameh

Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Released In Period Weighted Average Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReleasedInPeriodWeightedAverageFairValue

0

CY2015

ameh

Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodIntrinsicValue

0

CY2014Q1

ameh

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageIntrinsicValue

1.10

CY2015Q1

ameh

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageIntrinsicValue

1.50

CY2015Q1

ameh

Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Per Share Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAveragePerShareIntrinsicValue

2.40

CY2014Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber

3752000

shares

CY2014Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted

ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted

0

shares

CY2015

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted

ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted

184000

shares

CY2014Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised

ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised

0

shares

CY2015

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised

ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised

183996

shares

CY2014Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber

3752000

shares

CY2015Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber

3752004

shares

CY2015Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber

3651675

shares

CY2014

ameh

Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term Beginning

ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning

P1Y

CY2014Q1

ameh

Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term Beginning

ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning

P9M18D

CY2015

ameh

Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term Beginning

ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning

P1M6D

CY2014Q1

ameh

Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term Granted

ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted

P0Y

CY2015

ameh

Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term Granted

ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted

P0Y

CY2014Q1

ameh

Sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionequityinstrumentsoutstandingweightedaverageremainingcontractualtermreleased

P0Y

CY2015

ameh

Sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionequityinstrumentsoutstandingweightedaverageremainingcontractualtermreleased

P0Y

CY2014Q1

ameh

Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Aggregate Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAggregateIntrinsicValue

0.02

CY2014Q1

ameh

Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted In Period Aggregate Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodAggregateIntrinsicValue

0

CY2014Q1

ameh

Class Of Warrant Or Right Granted Intrinsic Value

ClassOfWarrantOrRightGrantedIntrinsicValue

0

CY2015

ameh

Class Of Warrant Or Right Granted Intrinsic Value

ClassOfWarrantOrRightGrantedIntrinsicValue

0

CY2014Q1

ameh

Class Of Warrant Or Right Exercised

ClassOfWarrantOrRightExercised

0

CY2015

ameh

Class Of Warrant Or Right Exercised

ClassOfWarrantOrRightExercised

0

CY2014Q1

ameh

Class Of Warrant Or Right Cancelled

ClassOfWarrantOrRightCancelled

0

CY2015

ameh

Class Of Warrant Or Right Cancelled

ClassOfWarrantOrRightCancelled

0

CY2014Q1

ameh

Class Of Warrant Or Right Outstanding Intrinsic Value

ClassOfWarrantOrRightOutstandingIntrinsicValue

0.20

CY2014Q1

us-gaap

Class Of Warrant Or Right Outstanding

ClassOfWarrantOrRightOutstanding

314500

shares

CY2014Q1

ameh

Number Of Warrants Granted

NumberOfWarrantsGranted

400000

shares

CY2015

ameh

Number Of Warrants Granted

NumberOfWarrantsGranted

200000

shares

CY2014Q1

ameh

Number Of Warrants Exercised

NumberOfWarrantsExercised

0

shares

CY2015

ameh

Number Of Warrants Exercised

NumberOfWarrantsExercised

0

shares

CY2014Q1

ameh

Class Of Warrant Or Right Cancelled In Period

ClassOfWarrantOrRightCancelledInPeriod

0

shares

CY2015

ameh

Class Of Warrant Or Right Cancelled In Period

ClassOfWarrantOrRightCancelledInPeriod

0

shares

CY2014Q1

us-gaap

Class Of Warrant Or Right Outstanding

ClassOfWarrantOrRightOutstanding

714500

shares

CY2015Q1

us-gaap

Class Of Warrant Or Right Outstanding

ClassOfWarrantOrRightOutstanding

914500

shares

CY2015

ameh

Class Of Warrant Or Right Issued In Period

ClassOfWarrantOrRightIssuedInPeriod

914500

shares

CY2015

ameh

Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term

ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm

P4Y3M18D

CY2014

us-gaap

Deferred Income Tax Expense Benefit

DeferredIncomeTaxExpenseBenefit

0

USD

CY2014Q1

us-gaap

Deferred Income Tax Expense Benefit

DeferredIncomeTaxExpenseBenefit

4954

USD

CY2015

us-gaap

Deferred Income Tax Expense Benefit

DeferredIncomeTaxExpenseBenefit

-51922

USD

CY2014

us-gaap

Adjustment For Amortization

AdjustmentForAmortization

255396

USD

CY2014Q1

us-gaap

Adjustment For Amortization

AdjustmentForAmortization

25965

USD

CY2015

us-gaap

Adjustment For Amortization

AdjustmentForAmortization

121578

USD

CY2014

us-gaap

Amortization Of Debt Discount Premium

AmortizationOfDebtDiscountPremium

136751

USD

CY2014Q1

us-gaap

Amortization Of Debt Discount Premium

AmortizationOfDebtDiscountPremium

19406

USD

CY2015

us-gaap

Amortization Of Debt Discount Premium

AmortizationOfDebtDiscountPremium

400394

USD

CY2014

us-gaap

Increase Decrease In Accounts Receivable

IncreaseDecreaseInAccountsReceivable

-72916

USD

CY2014Q1

us-gaap

Increase Decrease In Accounts Receivable

IncreaseDecreaseInAccountsReceivable

-1128

USD

CY2015

us-gaap

Increase Decrease In Accounts Receivable

IncreaseDecreaseInAccountsReceivable

912205

USD

CY2014

us-gaap

Increase Decrease In Other Receivables

IncreaseDecreaseInOtherReceivables

0

USD

CY2014Q1

us-gaap

Increase Decrease In Other Receivables

IncreaseDecreaseInOtherReceivables

0

USD

CY2015

us-gaap

Increase Decrease In Other Receivables

IncreaseDecreaseInOtherReceivables

188236

USD

CY2014

us-gaap

Increase Decrease Due From Affiliates

IncreaseDecreaseDueFromAffiliates

-4049

USD

CY2014Q1

us-gaap

Increase Decrease Due From Affiliates

IncreaseDecreaseDueFromAffiliates

22442

USD

CY2015

us-gaap

Increase Decrease Due From Affiliates

IncreaseDecreaseDueFromAffiliates

-55358

USD

CY2014

us-gaap

Increase Decrease In Prepaid Expense

IncreaseDecreaseInPrepaidExpense

-19084

USD

CY2014Q1

us-gaap

Increase Decrease In Prepaid Expense

IncreaseDecreaseInPrepaidExpense

-11342

USD

CY2015

us-gaap

Increase Decrease In Prepaid Expense

IncreaseDecreaseInPrepaidExpense

118054

USD

CY2014

us-gaap

Increase Decrease In Other Operating Assets

IncreaseDecreaseInOtherOperatingAssets

27700

USD

CY2014Q1

us-gaap

Increase Decrease In Other Operating Assets

IncreaseDecreaseInOtherOperatingAssets

2952

USD

CY2015

us-gaap

Increase Decrease In Other Operating Assets

IncreaseDecreaseInOtherOperatingAssets

106510

USD

CY2014

us-gaap

Increase Decrease In Accounts Payable And Accrued Liabilities

IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

455738

USD

CY2014Q1

us-gaap

Increase Decrease In Accounts Payable And Accrued Liabilities

IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

621360

USD

CY2015

us-gaap

Increase Decrease In Accounts Payable And Accrued Liabilities

IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

851277

USD

CY2014

ameh

Increase Decrease In Medical Liabilities

IncreaseDecreaseInMedicalLiabilities

0

USD

CY2014Q1

ameh

Increase Decrease In Medical Liabilities

IncreaseDecreaseInMedicalLiabilities

0

USD

CY2015

ameh

Increase Decrease In Medical Liabilities

IncreaseDecreaseInMedicalLiabilities

249610

USD

CY2014

us-gaap

Net Cash Provided By Used In Operating Activities Continuing Operations

NetCashProvidedByUsedInOperatingActivitiesContinuingOperations

-1478205

USD

CY2014Q1

us-gaap

Net Cash Provided By Used In Operating Activities Continuing Operations

NetCashProvidedByUsedInOperatingActivitiesContinuingOperations

-8895

USD

CY2015

us-gaap

Net Cash Provided By Used In Operating Activities Continuing Operations

NetCashProvidedByUsedInOperatingActivitiesContinuingOperations

-271910

USD

CY2014

us-gaap

Payments To Acquire Businesses Net Of Cash Acquired

PaymentsToAcquireBusinessesNetOfCashAcquired

250000

USD

CY2014Q1

us-gaap

Payments To Acquire Businesses Net Of Cash Acquired

PaymentsToAcquireBusinessesNetOfCashAcquired

0

USD

CY2015

us-gaap

Payments To Acquire Businesses Net Of Cash Acquired

PaymentsToAcquireBusinessesNetOfCashAcquired

3356145

USD

CY2014

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

22931

USD

CY2014Q1

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

12228

USD

CY2015

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

44509

USD

CY2014

us-gaap

Net Cash Provided By Used In Investing Activities Continuing Operations

NetCashProvidedByUsedInInvestingActivitiesContinuingOperations

-272931

USD

CY2014Q1

us-gaap

Net Cash Provided By Used In Investing Activities Continuing Operations

NetCashProvidedByUsedInInvestingActivitiesContinuingOperations

-12228

USD

CY2015

us-gaap

Net Cash Provided By Used In Investing Activities Continuing Operations

NetCashProvidedByUsedInInvestingActivitiesContinuingOperations

-3200375

USD

CY2014

us-gaap

Proceeds From Convertible Debt

ProceedsFromConvertibleDebt

220000

USD

CY2014Q1

us-gaap

Proceeds From Convertible Debt

ProceedsFromConvertibleDebt

0

USD

CY2015

us-gaap

Proceeds From Convertible Debt

ProceedsFromConvertibleDebt

2000000

USD

CY2014

ameh

Principal Payments On Term Note Payable

PrincipalPaymentsOnTermNotePayable

530000

USD

CY2014Q1

ameh

Principal Payments On Term Note Payable

PrincipalPaymentsOnTermNotePayable

0

USD

CY2015

ameh

Principal Payments On Term Note Payable

PrincipalPaymentsOnTermNotePayable

936083

USD

CY2014

us-gaap

Proceeds From Payments To Minority Shareholders

ProceedsFromPaymentsToMinorityShareholders

0

USD

CY2014Q1

us-gaap

Proceeds From Payments To Minority Shareholders

ProceedsFromPaymentsToMinorityShareholders

0

USD

CY2015

us-gaap

Proceeds From Payments To Minority Shareholders

ProceedsFromPaymentsToMinorityShareholders

725278

USD

CY2014

us-gaap

Payments To Minority Shareholders

PaymentsToMinorityShareholders

240000

USD

CY2014Q1

us-gaap

Payments To Minority Shareholders

PaymentsToMinorityShareholders

200000

USD

CY2015

us-gaap

Payments To Minority Shareholders

PaymentsToMinorityShareholders

600000

USD

CY2014

us-gaap

Proceeds From Issuance Of Common Stock

ProceedsFromIssuanceOfCommonStock

730000

USD

CY2014Q1

us-gaap

Proceeds From Issuance Of Common Stock

ProceedsFromIssuanceOfCommonStock

2000000

USD

CY2015

us-gaap

Proceeds From Issuance Of Common Stock

ProceedsFromIssuanceOfCommonStock

0

USD

CY2014

us-gaap

Payments Of Debt Issuance Costs

PaymentsOfDebtIssuanceCosts

258151

USD

CY2014Q1

us-gaap

Payments Of Debt Issuance Costs

PaymentsOfDebtIssuanceCosts

232676

USD

CY2015

us-gaap

Payments Of Debt Issuance Costs

PaymentsOfDebtIssuanceCosts

533646

USD

CY2015Q1

us-gaap

Finite Lived Intangible Assets Amortization Expense Year Five

FiniteLivedIntangibleAssetsAmortizationExpenseYearFive

40894

USD

CY2015Q1

us-gaap

Finite Lived Intangible Assets Net

FiniteLivedIntangibleAssetsNet

673257

USD

CY2015

ameh

Warrants To Purchase Common Stock

WarrantsToPurchaseCommonStock

30000

shares

CY2015

us-gaap

Finitelived Intangible Assets Acquired1

FinitelivedIntangibleAssetsAcquired1

2400

USD

CY2014Q1

us-gaap

Earnings Per Share Basic And Diluted

EarningsPerShareBasicAndDiluted

-0.16

CY2015

dei

Trading Symbol

TradingSymbol

AMEH

CY2015Q3

dei

Entity Common Stock Shares Outstanding

EntityCommonStockSharesOutstanding

4863389

shares

CY2014

us-gaap

Net Cash Provided By Used In Financing Activities Continuing Operations

NetCashProvidedByUsedInFinancingActivitiesContinuingOperations

2025816

USD

CY2014Q1

us-gaap

Net Cash Provided By Used In Financing Activities Continuing Operations

NetCashProvidedByUsedInFinancingActivitiesContinuingOperations

5401194

USD

CY2015

us-gaap

Net Cash Provided By Used In Financing Activities Continuing Operations

NetCashProvidedByUsedInFinancingActivitiesContinuingOperations

1655049

USD

CY2014

us-gaap

Cash And Cash Equivalents Period Increase Decrease

CashAndCashEquivalentsPeriodIncreaseDecrease

274680

USD

CY2014Q1

us-gaap

Cash And Cash Equivalents Period Increase Decrease

CashAndCashEquivalentsPeriodIncreaseDecrease

5380071

USD

CY2015

us-gaap

Cash And Cash Equivalents Period Increase Decrease

CashAndCashEquivalentsPeriodIncreaseDecrease

-1817236

USD

CY2013Q1

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

1176727

USD

CY2014

us-gaap

Interest Paid

InterestPaid

247465

USD

CY2014Q1

us-gaap

Interest Paid

InterestPaid

84720

USD

CY2015

us-gaap

Interest Paid

InterestPaid

768845

USD

CY2014

us-gaap

Income Taxes Paid

IncomeTaxesPaid

19513

USD

CY2014Q1

us-gaap

Income Taxes Paid

IncomeTaxesPaid

3824

USD

CY2015

us-gaap

Income Taxes Paid

IncomeTaxesPaid

32197

USD

CY2014

ameh

Convertible Note Warrant

ConvertibleNoteWarrant

50936

USD

CY2014Q1

ameh

Convertible Note Warrant

ConvertibleNoteWarrant

0

USD

CY2015

ameh

Convertible Note Warrant

ConvertibleNoteWarrant

487620

USD

CY2014

us-gaap

Debt Instrument Convertible Beneficial Conversion Feature

DebtInstrumentConvertibleBeneficialConversionFeature

0

USD

CY2014Q1

us-gaap

Debt Instrument Convertible Beneficial Conversion Feature

DebtInstrumentConvertibleBeneficialConversionFeature

0

USD

CY2015

us-gaap

Debt Instrument Convertible Beneficial Conversion Feature

DebtInstrumentConvertibleBeneficialConversionFeature

578155

USD

CY2014

us-gaap

Other Significant Noncash Transaction Value Of Consideration Given1

OtherSignificantNoncashTransactionValueOfConsiderationGiven1

0

USD

CY2014Q1

us-gaap

Other Significant Noncash Transaction Value Of Consideration Given1

OtherSignificantNoncashTransactionValueOfConsiderationGiven1

0

USD

CY2015

us-gaap

Other Significant Noncash Transaction Value Of Consideration Given1

OtherSignificantNoncashTransactionValueOfConsiderationGiven1

132000

USD

CY2015Q1

ameh

Common Stock Issuable Upon Conversion Of Convertible Nine Senior Notes

CommonStockIssuableUponConversionOfConvertibleNineSeniorNotes

275000

shares

CY2015Q1

ameh

Common Stock Issuable Upon Conversion Of Convertible Eight Senior Notes

CommonStockIssuableUponConversionOfConvertibleEightSeniorNotes

200000

shares

CY2015Q1

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant

ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

90000

shares

CY2014

us-gaap

Cash Acquired From Acquisition

CashAcquiredFromAcquisition

660893

USD

CY2014Q1

us-gaap

Cash Acquired From Acquisition

CashAcquiredFromAcquisition

660893

USD

CY2015

us-gaap

Cash Acquired From Acquisition

CashAcquiredFromAcquisition

660893

USD

CY2014

us-gaap

Earnings Per Share Basic And Diluted

EarningsPerShareBasicAndDiluted

-1.37

CY2015

us-gaap

Earnings Per Share Basic And Diluted

EarningsPerShareBasicAndDiluted

-0.37

CY2014

us-gaap

Weighted Average Number Of Share Outstanding Basic And Diluted

WeightedAverageNumberOfShareOutstandingBasicAndDiluted

3666165

shares

CY2014Q1

us-gaap

Weighted Average Number Of Share Outstanding Basic And Diluted

WeightedAverageNumberOfShareOutstandingBasicAndDiluted

4717521

shares

CY2015

us-gaap

Weighted Average Number Of Share Outstanding Basic And Diluted

WeightedAverageNumberOfShareOutstandingBasicAndDiluted

4891652

shares

CY2014

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

24783

USD

CY2014Q1

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

23000

USD

CY2015

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

0

USD

CY2014Q4

us-gaap

Capital

613889

USD

CY2014Q4

ameh

Cash Received Monthly

CashReceivedMonthly

15000

USD

CY2015Q1

us-gaap

Business Acquisition Cost Of Acquired Entity Transaction Costs

BusinessAcquisitionCostOfAcquiredEntityTransactionCosts

16000

USD

CY2014Q4

ameh

Description For Purchase Agreement Interest

DescriptionForPurchaseAgreementInterest

51% of the membership interests

CY2014

us-gaap

Proceeds From Lines Of Credit

ProceedsFromLinesOfCredit

2811878

USD

CY2014Q1

us-gaap

Proceeds From Lines Of Credit

ProceedsFromLinesOfCredit

7000000

USD

CY2015

us-gaap

Proceeds From Lines Of Credit

ProceedsFromLinesOfCredit

1000000

USD

CY2014

us-gaap

Payments For Repurchase Of Common Stock

PaymentsForRepurchaseOfCommonStock

0

USD

CY2014Q1

us-gaap

Payments For Repurchase Of Common Stock

PaymentsForRepurchaseOfCommonStock

0

USD

CY2015

us-gaap

Payments For Repurchase Of Common Stock

PaymentsForRepurchaseOfCommonStock

500

USD

CY2014

us-gaap

Repayments Of Other Short Term Debt

RepaymentsOfOtherShortTermDebt

707911

USD

CY2014Q1

us-gaap

Repayments Of Other Short Term Debt

RepaymentsOfOtherShortTermDebt

98252

USD

CY2015

us-gaap

Repayments Of Other Short Term Debt

RepaymentsOfOtherShortTermDebt

0

USD

CY2014

us-gaap

Noncontrolling Interest Increase From Subsidiary Equity Issuance

NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance

0

USD

CY2014Q1

us-gaap

Noncontrolling Interest Increase From Subsidiary Equity Issuance

NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance

0

USD

CY2015

us-gaap

Noncontrolling Interest Increase From Subsidiary Equity Issuance

NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance

274148

USD

CY2015

us-gaap

Stock Repurchased During Period Value

StockRepurchasedDuringPeriodValue

500

USD

CY2014Q1

us-gaap

Repayments Of Lines Of Credit

RepaymentsOfLinesOfCredit

2811878

USD

CY2015

us-gaap

Repayments Of Lines Of Credit

RepaymentsOfLinesOfCredit

0

USD

CY2014Q1

ameh

Payment Of Medical Clinic Acquisition Notes Payable

PaymentOfMedicalClinicAcquisitionNotesPayable

256000

USD

CY2015

ameh

Payment Of Medical Clinic Acquisition Notes Payable

PaymentOfMedicalClinicAcquisitionNotesPayable

0

USD

CY2014Q1

ameh

Discount On Term Loan

DiscountOnTermLoan

1254363

USD

CY2015

ameh

Discount On Term Loan

DiscountOnTermLoan

0

USD

CY2014Q1

ameh

Shares Issued In Connection With Notes Redemption

SharesIssuedInConnectionWithNotesRedemption

51748

USD

CY2015

ameh

Shares Issued In Connection With Notes Redemption

SharesIssuedInConnectionWithNotesRedemption

0

USD

CY2014Q1

ameh

Discount On Shares Issuance

DiscountOnSharesIssuance

1100261

USD

CY2015

ameh

Discount On Shares Issuance

DiscountOnSharesIssuance

0

USD

CY2014Q1

ameh

Fair Value Of Warrant Liabilities

FairValueOfWarrantLiabilities

2354624

USD

CY2015

ameh

Fair Value Of Warrant Liabilities

FairValueOfWarrantLiabilities

0

USD

CY2015Q1

us-gaap

Deferred Finance Costs Current Net

DeferredFinanceCostsCurrentNet

513646

USD

CY2014Q1

us-gaap

Deferred Finance Costs Current Net

DeferredFinanceCostsCurrentNet

0

USD

CY2014Q1

us-gaap

Deferred Finance Costs Current Net

DeferredFinanceCostsCurrentNet

97806

USD

CY2014

us-gaap

Minority Interest Period Increase Decrease

MinorityInterestPeriodIncreaseDecrease

-240000

USD

CY2014Q1

us-gaap

Minority Interest Period Increase Decrease

MinorityInterestPeriodIncreaseDecrease

-200000

USD

CY2015

us-gaap

Minority Interest Period Increase Decrease

MinorityInterestPeriodIncreaseDecrease

-600000

USD

CY2014Q1

ameh

Stock Issued During Period Value For Financing

StockIssuedDuringPeriodValueForFinancing

868236

USD

CY2014Q1

us-gaap

Stock Issued During Period Value Conversion Of Convertible Securities

StockIssuedDuringPeriodValueConversionOfConvertibleSecurities

51748

USD

CY2014

us-gaap

Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature

AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature

509890

USD

CY2014

us-gaap

Debt Conversion Converted Instrument Amount1

DebtConversionConvertedInstrumentAmount1

864298

USD

CY2014

us-gaap

Stock Issued During Period Value New Issues

StockIssuedDuringPeriodValueNewIssues

730000

USD

CY2014

us-gaap

Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition

AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition

1252378

USD

CY2014

ameh

Adjustment To Additional Paid In Capital Share Based Compensation Non Vested Shares Requisite Service Period Recognition

AdjustmentToAdditionalPaidInCapitalShareBasedCompensationNonVestedSharesRequisiteServicePeriodRecognition

333838

USD

CY2014

us-gaap

Stock Issued During Period Value Other

StockIssuedDuringPeriodValueOther

45000

USD

CY2014

us-gaap

Stock Issued During Period Value Share Based Compensation

StockIssuedDuringPeriodValueShareBasedCompensation

730975

USD

CY2014

ameh

Discount On Term Loan

DiscountOnTermLoan

0

USD

CY2014

ameh

Shares Issued In Connection With Notes Redemption

SharesIssuedInConnectionWithNotesRedemption

864298

USD

CY2014

ameh

Fair Value Of Warrant Liabilities

FairValueOfWarrantLiabilities

0

USD

CY2014

ameh

Discount On Shares Issuance

DiscountOnSharesIssuance

0

USD

CY2014

ameh

Payment Of Medical Clinic Acquisition Notes Payable

PaymentOfMedicalClinicAcquisitionNotesPayable

0

USD

CY2014

us-gaap

Repayments Of Lines Of Credit

RepaymentsOfLinesOfCredit

0

USD

CY2015

us-gaap

Marketable Securities Gain Loss

MarketableSecuritiesGainLoss

49791

USD

CY2014Q1

us-gaap

Marketable Securities Gain Loss

MarketableSecuritiesGainLoss

0

USD

CY2014

us-gaap

Marketable Securities Gain Loss

MarketableSecuritiesGainLoss

0

USD

CY2015

us-gaap

Provision For Doubtful Accounts

ProvisionForDoubtfulAccounts

64811

USD

CY2014Q1

us-gaap

Provision For Doubtful Accounts

ProvisionForDoubtfulAccounts

0

USD

CY2014

us-gaap

Provision For Doubtful Accounts

ProvisionForDoubtfulAccounts

0

USD

CY2015Q1

us-gaap

Property Plant And Equipment Gross

PropertyPlantAndEquipmentGross

1142447

USD

CY2014Q1

us-gaap

Property Plant And Equipment Gross

PropertyPlantAndEquipmentGross

447862

USD

CY2014Q1

us-gaap

Property Plant And Equipment Gross

PropertyPlantAndEquipmentGross

438083

USD

CY2015Q1

us-gaap

Accumulated Depreciation Depletion And Amortization Property Plant And Equipment

AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

559977

USD

CY2014Q1

us-gaap

Accumulated Depreciation Depletion And Amortization Property Plant And Equipment

AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

352914

USD

CY2014Q1

us-gaap

Accumulated Depreciation Depletion And Amortization Property Plant And Equipment

AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

352398

USD

CY2015

us-gaap

Increase In Restricted Cash

IncreaseInRestrictedCash

510000

USD

CY2014Q1

us-gaap

Increase In Restricted Cash

IncreaseInRestrictedCash

0

USD

CY2015Q2

us-gaap

Stockholders Equity Reverse Stock Split

StockholdersEquityReverseStockSplit

1-for-10

CY2015Q1

us-gaap

Operating Leases Future Minimum Payments Next Rolling Twelve Months

OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths

771754

USD

CY2015Q1

us-gaap

Operating Leases Future Minimum Payments Due In Rolling Year Two

OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo

834522

USD

CY2015Q1

us-gaap

Operating Leases Future Minimum Payments Due In Rolling Year Three

OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree

916395

USD

CY2015Q1

us-gaap

Operating Leases Future Minimum Payments Due In Rolling Year Four

OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour

920630

USD

CY2015Q1

us-gaap

Operating Leases Future Minimum Payments Due In Rolling Year Five

OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive

905117

USD

CY2015Q1

us-gaap

Operating Leases Future Minimum Payments Due In Rolling After Year Five

OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive

2482251

USD

CY2015Q1

us-gaap

Operating Leases Future Minimum Payments Due

OperatingLeasesFutureMinimumPaymentsDue

6830669

USD

CY2014Q1

us-gaap

Lease And Rental Expense

LeaseAndRentalExpense

39735

USD

CY2015

us-gaap

Lease And Rental Expense

LeaseAndRentalExpense

685579

USD

CY2014

us-gaap

Lease And Rental Expense

LeaseAndRentalExpense

210302

USD

CY2015

us-gaap

Proceeds From Sale And Maturity Of Marketable Securities

ProceedsFromSaleAndMaturityOfMarketableSecurities

438884

USD

CY2014Q1

us-gaap

Proceeds From Sale And Maturity Of Marketable Securities

ProceedsFromSaleAndMaturityOfMarketableSecurities

0

USD

CY2014

us-gaap

Proceeds From Sale And Maturity Of Marketable Securities

ProceedsFromSaleAndMaturityOfMarketableSecurities

0

USD

CY2014Q1

us-gaap

Intangible Assets Gross Excluding Goodwill

IntangibleAssetsGrossExcludingGoodwill

68400

USD

CY2015Q1

us-gaap

Intangible Assets Gross Excluding Goodwill

IntangibleAssetsGrossExcludingGoodwill

1513400

USD

CY2014Q1

us-gaap

Intangible Assets Gross Excluding Goodwill

IntangibleAssetsGrossExcludingGoodwill

68400

USD

CY2014Q1

ameh

Settlement Of Stock Issuable Liability With Issuance Of Shares

SettlementOfStockIssuableLiabilityWithIssuanceOfShares

0

USD

CY2014

ameh

Settlement Of Stock Issuable Liability With Issuance Of Shares

SettlementOfStockIssuableLiabilityWithIssuanceOfShares

159334

USD

CY2015

ameh

Conversion Of Line Of Credit To Notes Payable

ConversionOfLineOfCreditToNotesPayable

0

USD

CY2014Q1

ameh

Conversion Of Line Of Credit To Notes Payable

ConversionOfLineOfCreditToNotesPayable

0

USD

CY2014

ameh

Conversion Of Line Of Credit To Notes Payable

ConversionOfLineOfCreditToNotesPayable

509890

USD

CY2015

us-gaap

Noncash Or Part Noncash Acquisition Other Liabilities Assumed1

NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1

218183

USD

CY2014Q1

us-gaap

Noncash Or Part Noncash Acquisition Other Liabilities Assumed1

NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1

0

USD

CY2014Q1

us-gaap

Notes Issued1

NotesIssued1

0

USD

CY2014

us-gaap

Notes Issued1

NotesIssued1

299900

USD

CY2015

ameh

Settlement Of Stock Issuable Liability With Issuance Of Shares

SettlementOfStockIssuableLiabilityWithIssuanceOfShares

0

USD

CY2015

us-gaap

Use Of Estimates

UseOfEstimates

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>Use of Estimates</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may materially differ from these estimates under different assumptions or conditions.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

CY2014Q1

us-gaap

Allowance For Doubtful Accounts Receivable

AllowanceForDoubtfulAccountsReceivable

30670

USD

CY2014Q1

us-gaap

Allowance For Doubtful Accounts Receivable

AllowanceForDoubtfulAccountsReceivable

50474

USD

CY2013Q1

us-gaap

Allowance For Doubtful Accounts Receivable

AllowanceForDoubtfulAccountsReceivable

78822

USD

CY2015

us-gaap

Allowance For Doubtful Accounts Receivable Period Increase Decrease

AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease

64811

USD

CY2014Q1

us-gaap

Allowance For Doubtful Accounts Receivable Period Increase Decrease

AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease

0

USD

CY2014

us-gaap

Allowance For Doubtful Accounts Receivable Period Increase Decrease

AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease

0

USD

CY2015

us-gaap

Allowance For Doubtful Accounts Receivable Write Offs

AllowanceForDoubtfulAccountsReceivableWriteOffs

0

USD

CY2014Q1

us-gaap

Allowance For Doubtful Accounts Receivable Write Offs

AllowanceForDoubtfulAccountsReceivableWriteOffs

19804

USD

CY2014

us-gaap

Allowance For Doubtful Accounts Receivable Write Offs

AllowanceForDoubtfulAccountsReceivableWriteOffs

28348

USD

CY2015Q1

us-gaap

Allowance For Doubtful Accounts Receivable

AllowanceForDoubtfulAccountsReceivable

95481

USD

CY2015

us-gaap

Noncontrolling Interest Increase From Business Combination

NoncontrollingInterestIncreaseFromBusinessCombination

191154

USD

CY2014Q1

us-gaap

Noncontrolling Interest Increase From Business Combination

NoncontrollingInterestIncreaseFromBusinessCombination

0

USD

CY2014

us-gaap

Noncontrolling Interest Increase From Business Combination

NoncontrollingInterestIncreaseFromBusinessCombination

0

USD

CY2015

ameh

Issuance Of Common Stock Value In Payment Of Financing Cost

IssuanceOfCommonStockValueInPaymentOfFinancingCost

0

USD

CY2014Q1

ameh

Issuance Of Common Stock Value In Payment Of Financing Cost

IssuanceOfCommonStockValueInPaymentOfFinancingCost

0

USD

CY2014

ameh

Issuance Of Common Stock Value In Payment Of Financing Cost

IssuanceOfCommonStockValueInPaymentOfFinancingCost

45000

USD

CY2015

us-gaap

Notes Issued1

NotesIssued1

0

USD

CY2014

us-gaap

Noncash Or Part Noncash Acquisition Other Liabilities Assumed1

NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1

0

USD

CY2015

ameh

Partial Value Of Shares Paid Out In Connection With Reverse Stock Split

PartialValueOfSharesPaidOutInConnectionWithReverseStockSplit

0

USD

CY2014

us-gaap

Increase In Restricted Cash

IncreaseInRestrictedCash

0

USD

CY2015

us-gaap

Depreciation And Amortization

DepreciationAndAmortization

207063

USD

CY2014Q1

us-gaap

Depreciation And Amortization

DepreciationAndAmortization

516

USD

CY2014

us-gaap

Depreciation And Amortization

DepreciationAndAmortization

25388

USD

CY2015Q1

ameh

Percentage Of Interest Rate For Certificates

PercentageOfInterestRateForCertificates

0.0015

pure

CY2015

us-gaap

Business Combination Consideration Transferred Liabilities Incurred

BusinessCombinationConsiderationTransferredLiabilitiesIncurred

375000

USD

CY2014

us-gaap

Deferred State And Local Income Tax Expense Benefit

DeferredStateAndLocalIncomeTaxExpenseBenefit

0

USD

CY2014Q1

us-gaap

Convertible Long Term Notes Payable

ConvertibleLongTermNotesPayable

1100522

USD

CY2015

ameh

Cash Increase On Consolidation Of Variable Interest Entity

CashIncreaseOnConsolidationOfVariableInterestEntity

271395

USD

CY2014Q1

ameh

Cash Increase On Consolidation Of Variable Interest Entity

CashIncreaseOnConsolidationOfVariableInterestEntity

0

USD

CY2014

ameh

Cash Increase On Consolidation Of Variable Interest Entity

CashIncreaseOnConsolidationOfVariableInterestEntity

0

USD

CY2015Q1

us-gaap

Deferred Tax Assets Net Current

DeferredTaxAssetsNetCurrent

-27156

USD

CY2014Q1

us-gaap

Deferred Tax Assets Net Current

DeferredTaxAssetsNetCurrent

0

USD

CY2014Q1

us-gaap

Deferred Tax Assets Net Current

DeferredTaxAssetsNetCurrent

0

USD

CY2015Q1

us-gaap

Convertible Notes Payable Current

ConvertibleNotesPayableCurrent

1037818

USD

CY2014Q1

us-gaap

Convertible Notes Payable Current

ConvertibleNotesPayableCurrent

0

USD

CY2014Q1

us-gaap

Convertible Notes Payable Current

ConvertibleNotesPayableCurrent

0

USD

CY2015Q1

us-gaap

Convertible Long Term Notes Payable

ConvertibleLongTermNotesPayable

1457103

USD

CY2014Q1

us-gaap

Convertible Long Term Notes Payable

ConvertibleLongTermNotesPayable

962978

USD

CY2015

us-gaap

Concentration Risk Credit Risk

ConcentrationRiskCreditRisk

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Concentrations</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The Company had major payors that contributed the following percentage of net revenue:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>Year Ended<br/> March 31,<br/> 2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>Two Months<br/> Ended<br/> March 31,<br/> 2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>Year<br/> Ended<br/> January<br/> 31, 2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div>Medicare/Medi-Cal</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>34.8</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>14.3</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>17.8</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div>L.A Care</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>13.2</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>12.1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>*</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div>Healthnet</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>12.3</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>*</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="6%"> <div>*</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="33%"> <div>Hollywood Presbyterian</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; BACKGROUND: #ffffff; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="6%"> <div>*</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; BACKGROUND: #ffffff; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; BACKGROUND: #ffffff; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="6%"> <div>11.8</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; BACKGROUND: #ffffff; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; BACKGROUND: #ffffff; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="6%"> <div>15.9</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="33%"> <div>California Hospital</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; BACKGROUND: #cceeff; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="6%"> <div>*</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; BACKGROUND: #cceeff; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; BACKGROUND: #cceeff; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="6%"> <div>11.6</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; BACKGROUND: #cceeff; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; BACKGROUND: #cceeff; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="6%"> <div>13.9</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Receivables from one of these payors amounted to the following percentage of total accounts receivable:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>March 31,<br/> 2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>March 31,<br/> 2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="7%" colspan="2"> <div>January 31,<br/> 2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div>Medicare/Medi-Cal</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>22.1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>21.7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="6%"> <div>31.5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif">  </div> <strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></strong> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">*   Represents less than 10%</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

CY2015Q1

ameh

Business Combination Consideration Transferred Accrued

BusinessCombinationConsiderationTransferredAccrued

125000

USD

CY2015Q1

us-gaap

Long Term Debt Maturities Repayments Of Principal In Next Twelve Months

LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths

1684765

USD

CY2015Q1

us-gaap

Long Term Debt Maturities Repayments Of Principal In Year Two

LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo

490000

USD

CY2015Q1

us-gaap

Long Term Debt Maturities Repayments Of Principal In Year Three

LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree

700000

USD

CY2015Q1

us-gaap

Long Term Debt Maturities Repayments Of Principal In Year Four

LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour

7847500

USD

CY2015Q1

us-gaap

Long Term Debt

LongTermDebt

10722265

USD

CY2015Q1

us-gaap

Cash

5014242

USD

CY2015Q1

us-gaap

Line Of Credit

LineOfCredit

380000

USD

CY2015

us-gaap

Current Federal Tax Expense Benefit

CurrentFederalTaxExpenseBenefit

147945

USD

CY2014Q1

us-gaap

Current Federal Tax Expense Benefit

CurrentFederalTaxExpenseBenefit

0

USD

CY2015

us-gaap

Current State And Local Tax Expense Benefit

CurrentStateAndLocalTaxExpenseBenefit

67769

USD

CY2014Q1

us-gaap

Current State And Local Tax Expense Benefit

CurrentStateAndLocalTaxExpenseBenefit

2866

USD

CY2015

us-gaap

Current Income Tax Expense Benefit

CurrentIncomeTaxExpenseBenefit

215714

USD

CY2014Q1

us-gaap

Current Income Tax Expense Benefit

CurrentIncomeTaxExpenseBenefit

2866

USD

CY2015

us-gaap

Deferred Federal Income Tax Expense Benefit

DeferredFederalIncomeTaxExpenseBenefit

-36390

USD

CY2014Q1

us-gaap

Deferred Federal Income Tax Expense Benefit

DeferredFederalIncomeTaxExpenseBenefit

3855

USD

CY2015

us-gaap

Deferred State And Local Income Tax Expense Benefit

DeferredStateAndLocalIncomeTaxExpenseBenefit

-15532

USD

CY2014Q1

us-gaap

Deferred State And Local Income Tax Expense Benefit

DeferredStateAndLocalIncomeTaxExpenseBenefit

1099

USD

CY2015Q1

us-gaap

Deferred Tax Assets State Taxes

DeferredTaxAssetsStateTaxes

-17062

USD

CY2014Q1

us-gaap

Deferred Tax Assets State Taxes

DeferredTaxAssetsStateTaxes

-589

USD

CY2014Q1

us-gaap

Deferred Tax Assets State Taxes

DeferredTaxAssetsStateTaxes

-3808

USD

CY2015Q1

us-gaap

Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost

DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost

-2177276

USD

CY2014Q1

us-gaap

Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost

DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost

-1675822

USD

CY2014Q1

us-gaap

Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost

DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost

-1649986

USD

CY2015Q1

us-gaap

Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Benefits

DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits

-1529

USD

CY2014Q1

us-gaap

Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Benefits

DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits

-1529

USD

CY2014Q1

us-gaap

Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Benefits

DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits

-1529

USD

CY2015Q1

us-gaap

Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other

DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther

0

USD

CY2014Q1

us-gaap

Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other

DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther

-28649

USD

CY2014Q1

us-gaap

Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other

DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther

-28649

USD

CY2015Q1

us-gaap

Deferred Tax Assets Gross Current

DeferredTaxAssetsGrossCurrent

-2261787

USD

CY2014Q1

us-gaap

Deferred Tax Assets Gross Current

DeferredTaxAssetsGrossCurrent

-1706589

USD

CY2014Q1

us-gaap

Deferred Tax Assets Gross Current

DeferredTaxAssetsGrossCurrent

-1683972

USD

CY2015Q1

us-gaap

Deferred Tax Assets Valuation Allowance Current

DeferredTaxAssetsValuationAllowanceCurrent

-2234631

USD

CY2014Q1

us-gaap

Deferred Tax Assets Valuation Allowance Current

DeferredTaxAssetsValuationAllowanceCurrent

-1706589

USD

CY2014Q1

us-gaap

Deferred Tax Assets Valuation Allowance Current

DeferredTaxAssetsValuationAllowanceCurrent

-1683972

USD

CY2014Q1

us-gaap

Deferred Tax Assets Valuation Allowance

DeferredTaxAssetsValuationAllowance

3963239

USD

CY2014Q1

us-gaap

Deferred Tax Assets Valuation Allowance

DeferredTaxAssetsValuationAllowance

4163638

USD

CY2015Q1

us-gaap

Deferred Tax Assets Operating Loss Carryforwards

DeferredTaxAssetsOperatingLossCarryforwards

-2208522

USD

CY2014Q1

us-gaap

Deferred Tax Assets Operating Loss Carryforwards

DeferredTaxAssetsOperatingLossCarryforwards

-2248422

USD

CY2014Q1

us-gaap

Deferred Tax Assets Operating Loss Carryforwards

DeferredTaxAssetsOperatingLossCarryforwards

-1990962

USD

CY2015Q1

us-gaap

Deferred Tax Liabilities Property Plant And Equipment

DeferredTaxLiabilitiesPropertyPlantAndEquipment

-3170

USD

CY2014Q1

us-gaap

Deferred Tax Liabilities Property Plant And Equipment

DeferredTaxLiabilitiesPropertyPlantAndEquipment

0

USD

CY2014Q1

us-gaap

Deferred Tax Liabilities Property Plant And Equipment

DeferredTaxLiabilitiesPropertyPlantAndEquipment

0

USD

CY2015Q1

us-gaap

Deferred Tax Assets Goodwill And Intangible Assets

DeferredTaxAssetsGoodwillAndIntangibleAssets

194883

USD

CY2014Q1

us-gaap

Deferred Tax Assets Goodwill And Intangible Assets

DeferredTaxAssetsGoodwillAndIntangibleAssets

4954

USD

CY2014Q1

us-gaap

Deferred Tax Assets Goodwill And Intangible Assets

DeferredTaxAssetsGoodwillAndIntangibleAssets

0

USD

CY2015Q1

us-gaap

Deferred Tax Assets Other Tax Carryforwards

DeferredTaxAssetsOtherTaxCarryforwards

-3558

USD

CY2014Q1

us-gaap

Deferred Tax Assets Other Tax Carryforwards

DeferredTaxAssetsOtherTaxCarryforwards

-8228

USD

CY2014Q1

us-gaap

Deferred Tax Assets Other Tax Carryforwards

DeferredTaxAssetsOtherTaxCarryforwards

-488704

USD

CY2015Q1

us-gaap

Deferred Tax Assets Gross Noncurrent

DeferredTaxAssetsGrossNoncurrent

-2014027

USD

CY2014Q1

us-gaap

Deferred Tax Assets Gross Noncurrent

DeferredTaxAssetsGrossNoncurrent

-2251696

USD

CY2014Q1

us-gaap

Deferred Tax Assets Gross Noncurrent

DeferredTaxAssetsGrossNoncurrent

-2479666

USD

CY2015Q1

us-gaap

Deferred Tax Assets Valuation Allowance Noncurrent

DeferredTaxAssetsValuationAllowanceNoncurrent

-2212398

USD

CY2014Q1

us-gaap

Deferred Tax Assets Valuation Allowance Noncurrent

DeferredTaxAssetsValuationAllowanceNoncurrent

-2256650

USD

CY2014Q1

us-gaap

Deferred Tax Assets Valuation Allowance Noncurrent

DeferredTaxAssetsValuationAllowanceNoncurrent

-2479666

USD

CY2015Q1

us-gaap

Deferred Tax Liabilities Noncurrent

DeferredTaxLiabilitiesNoncurrent

-198371

USD

CY2014Q1

us-gaap

Deferred Tax Liabilities Noncurrent

DeferredTaxLiabilitiesNoncurrent

-4954

USD

CY2014Q1

us-gaap

Deferred Tax Liabilities Noncurrent

DeferredTaxLiabilitiesNoncurrent

0

USD

CY2015

us-gaap

Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate

EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

0.340

pure

CY2014Q1

us-gaap

Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate

EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

0.340

pure

CY2015

us-gaap

Effective Income Tax Rate Reconciliation Nondeductible Expense Other

EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther

0.005

pure

CY2014Q1

us-gaap

Effective Income Tax Rate Reconciliation Nondeductible Expense Other

EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther

-0.001

pure

CY2015

ameh

Effective Income Tax Rate Reconciliation Change In Valuation Allowance

EffectiveIncomeTaxRateReconciliationChangeInValuationAllowance

-0.349

pure

CY2014Q1

ameh

Effective Income Tax Rate Reconciliation Change In Valuation Allowance

EffectiveIncomeTaxRateReconciliationChangeInValuationAllowance

-0.348

pure

CY2015

us-gaap

Effective Income Tax Rate Reconciliation Tax Credits

EffectiveIncomeTaxRateReconciliationTaxCredits

-0.138

pure

CY2014Q1

us-gaap

Effective Income Tax Rate Reconciliation Tax Credits

EffectiveIncomeTaxRateReconciliationTaxCredits

-0.011

pure

CY2014

us-gaap

Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate

EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

0.340

pure

CY2014

us-gaap

Effective Income Tax Rate Reconciliation Nondeductible Expense Other

EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther

0.032

pure

CY2014

ameh

Effective Income Tax Rate Reconciliation Change In Valuation Allowance

EffectiveIncomeTaxRateReconciliationChangeInValuationAllowance

-0.372

pure

CY2015Q1

us-gaap

Deferred Tax Assets Valuation Allowance

DeferredTaxAssetsValuationAllowance

4447029

USD

CY2015

us-gaap

Prior Period Reclassification Adjustment Description

PriorPeriodReclassificationAdjustmentDescription

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" align="left"><b><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Reclassifications</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Certain reclassifications have been made to the accompanying January 31, 2014 consolidated financial statements to conform them to March 31, 2014 and March 31, 2015 presentation. The reclassification is between deferred taxes and accounts payable and accrued liabilities for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4,954</font></font> on the consolidated balance sheets and statement of cash flows. There is also a reclassification of restricted cash of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">20,000</font> from current assets to non currents assets on the consolidated balance sheets.  <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

CY2014

us-gaap

Current Federal Tax Expense Benefit

CurrentFederalTaxExpenseBenefit

0

USD

CY2014

us-gaap

Current State And Local Tax Expense Benefit

CurrentStateAndLocalTaxExpenseBenefit

19513

USD

CY2014

us-gaap

Current Income Tax Expense Benefit

CurrentIncomeTaxExpenseBenefit

19513

USD

CY2014

us-gaap

Deferred Federal Income Tax Expense Benefit

DeferredFederalIncomeTaxExpenseBenefit

0

USD

CY2014

us-gaap

Effective Income Tax Rate Reconciliation Tax Credits

EffectiveIncomeTaxRateReconciliationTaxCredits

-0.004

pure

CY2015

us-gaap

Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount

AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

582248

shares

CY2014Q1

us-gaap

Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount

AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

577980

shares

CY2014

us-gaap

Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount

AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

670853

shares

CY2014

ameh

Finite Lived Intangible Assets Accumulated Amortization Addition

FiniteLivedIntangibleAssetsAccumulatedAmortizationAddition

2800

USD

CY2014

ameh

Finite Lived Intangible Assets Accumulated Amortization Addition

FiniteLivedIntangibleAssetsAccumulatedAmortizationAddition

5973

USD

CY2015Q1

ameh

Class Of Warrant Or Right Outstanding Intrinsic Value

ClassOfWarrantOrRightOutstandingIntrinsicValue

0.46

CY2015Q1

ameh

Common Shares Issued And Outstanding

CommonSharesIssuedAndOutstanding

4863389

shares

CY2015Q1

us-gaap

Common Stock Capital Shares Reserved For Future Issuance

CommonStockCapitalSharesReservedForFutureIssuance

7119389

shares

CY2015Q1

us-gaap

Deferred Tax Assets Tax Deferred Expense Other

DeferredTaxAssetsTaxDeferredExpenseOther

-65920

USD

CY2014Q1

us-gaap

Deferred Tax Assets Tax Deferred Expense Other

DeferredTaxAssetsTaxDeferredExpenseOther

0

USD

CY2014Q1

us-gaap

Deferred Tax Assets Tax Deferred Expense Other

DeferredTaxAssetsTaxDeferredExpenseOther

0

USD

CY2015

us-gaap

Effective Income Tax Rate Reconciliation State And Local Income Taxes

EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes

-0.032

pure

CY2014Q1

us-gaap

Effective Income Tax Rate Reconciliation State And Local Income Taxes

EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes

-0.004

pure

CY2014

us-gaap

Effective Income Tax Rate Reconciliation State And Local Income Taxes

EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes

-0.003

pure

CY2015

us-gaap

Effective Income Tax Rate Reconciliation Nondeductible Expense

EffectiveIncomeTaxRateReconciliationNondeductibleExpense

-0.059

pure

CY2014Q1

us-gaap

Effective Income Tax Rate Reconciliation Nondeductible Expense

EffectiveIncomeTaxRateReconciliationNondeductibleExpense

-0.001

pure

CY2014

us-gaap

Effective Income Tax Rate Reconciliation Nondeductible Expense

EffectiveIncomeTaxRateReconciliationNondeductibleExpense

-0.001

pure

CY2015

ameh

Effective Income Tax Rate Reconciliation Non Taxable Entities

EffectiveIncomeTaxRateReconciliationNonTaxableEntities

-0.043

pure

CY2014Q1

ameh

Effective Income Tax Rate Reconciliation Non Taxable Entities

EffectiveIncomeTaxRateReconciliationNonTaxableEntities

0.003

pure

CY2014

ameh

Effective Income Tax Rate Reconciliation Non Taxable Entities

EffectiveIncomeTaxRateReconciliationNonTaxableEntities

0

pure

CY2015Q1

us-gaap

Restricted Cash And Investments Current

RestrictedCashAndInvestmentsCurrent

530000

USD

CY2014Q1

us-gaap

Restricted Cash And Investments Current

RestrictedCashAndInvestmentsCurrent

20000

USD

CY2014Q1

us-gaap

Restricted Cash And Investments Current

RestrictedCashAndInvestmentsCurrent

20000

USD

CY2015

us-gaap

Nature Of Operations

NatureOfOperations

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>1.</strong>            <strong>Description of Business</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Apollo Medical Holdings, Inc. (the “Company” or “ApolloMed”) and its affiliated physician groups are a patient-centered, physician-centric integrated healthcare delivery company working to provide coordinated, outcomes-based medical care in a cost-effective manner. ApolloMed has built a company and culture that is focused on physicians providing high quality care, population management and care coordination for patients, particularly for senior patients and patients with multiple chronic conditions.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> ApolloMed serves Medicare, Medicaid and HMO patients and uninsured patients primarily in California, as well as in Mississippi and Ohio (where our ACO has recently begun operations). We primarily provide services to patients that are covered by private or public insurance, although we do derive a small portion of our revenue from non-insured patients. We provide care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups and health plans.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> ApolloMed’s physician network consists of hospitalists, primary care physicians and specialist physicians primarily through ApolloMed’s owned and affiliated physician groups. ApolloMed operates through the following subsidiaries: Apollo Medical Management, Inc. (“AMM”), Pulmonary Critical Care Management, Inc. (“PCCM”), Verdugo Medical Management, Inc. (“VMM”), and ApolloMed Accountable Care Organization, Inc. (“ApolloMed ACO”). Through its wholly-owned subsidiary, AMM, ApolloMed manages affiliated medical groups, which consist of ApolloMed Hospitalists (“AMH”), a hospitalist company, ApolloMed Care Clinic (“ACC”), Maverick Medical Group, Inc. (“MMG”), AKM Medical Group, Inc. (“AKM”), Southern California Heart Centers (“SCHC”) and Bay Area Hospitalist Associates, A Medical Corporation (BAHA). Through its wholly-owned subsidiary, PCCM, ApolloMed manages Los Angeles Lung Center (“LALC”), and through its wholly-owned subsidiary VMM, ApolloMed manages Eli Hendel, M.D., Inc. (“Hendel”). ApolloMed also has a controlling interest in ApolloMed Palliative Services, LLC (“ApolloMed Palliative”), which owns two Los Angeles-based companies, Best Choice Hospice Care LLC (“BCHC”) and Holistic Health Home Health Care Inc. (“HCHHA”). AMM, PCCM and VMM each operate as a physician practice management company and are in the business of providing management services to physician practice corporations under long-term management service agreements, pursuant to which AMM, PCCM or VMM, as applicable, manages all non-medical services for the affiliated medical group and has exclusive authority over all non-medical decision making related to ongoing business operations. ApolloMed ACO participates in the Medicare Shared Savings Program (“MSSP”), the goal of which is to improve the quality of patient care and outcomes through more efficient and coordinated approach among providers. ApolloMed ACO participates in the MSSP, the goal of which is to improve the quality of patient care and outcomes through more efficient and coordinated approach among providers. </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" align="left"><b>Liquidity and Capital Resources</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The Company has a history of operating losses and as of March 31, 2015 has an accumulated deficit of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">19,340,521</font>, and during the year ended March 31, 2015 net cash used in operating activities was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">271,910</font>.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The primary sources of liquidity as of March 31, 2015 include cash on hand of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,014,242</font> and availability under lines of credit of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">380,000</font>. Management has established a business plan, which they believe will result in future profitability. However, the Company may require additional funding to meet certain obligations until sufficient cash flows are generated from anticipated operations. Management believes that ongoing requirements for working capital, debt service and covenants compliance and planned capital expenditures will be adequately funded from current sources for at least the next twelve months. If available funds are not adequate, the Company may need to obtain additional sources of funds or reduce operations; however, there is no assurance that the Company will be successful in doing so.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>Change in Fiscal Year</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> On May 16, 2014, the Board of Directors of the Company approved a change to the Company's fiscal year end from January 31 to March 31.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

CY2015

ameh

Risk Pool Settlement Payment

RiskPoolSettlementPayment

-384869

USD

CY2014Q1

ameh

Risk Pool Settlement Payment

RiskPoolSettlementPayment

0

USD

CY2014

ameh

Risk Pool Settlement Payment

RiskPoolSettlementPayment

0

USD

CY2015Q1

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

785143

USD

CY2014Q1

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

0

USD

CY2014Q1

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

0

USD

CY2014Q1

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Net

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet

552561

USD

CY2014Q1

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Net

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet

285625

USD

CY2013Q1

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Net

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet

0

USD

CY2015

ameh

Liability For Unpaid Claims And Claims Adjustment Expense Accrual For Net Deficit From Full Risk Capitation Contracts

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAccrualForNetDeficitFromFullRiskCapitationContracts

544041

USD

CY2014Q1

ameh

Liability For Unpaid Claims And Claims Adjustment Expense Accrual For Net Deficit From Full Risk Capitation Contracts

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAccrualForNetDeficitFromFullRiskCapitationContracts

99936

USD

CY2014

ameh

Liability For Unpaid Claims And Claims Adjustment Expense Accrual For Net Deficit From Full Risk Capitation Contracts

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAccrualForNetDeficitFromFullRiskCapitationContracts

0

USD

CY2015Q1

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Net

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet

1260549

USD

CY2015

us-gaap

Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense

ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company’s medical liabilities was as follows:</div>   <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 95%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Year Ended<br/> March 31, 2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Two<br/> Months<br/> Ended<br/> March 31, 2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Year Ended<br/> January 31,<br/> 2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Balance, beginning of period</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>552,561</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>285,625</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Incurred health care costs:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Current year</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4,211,231</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>167,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>288,601</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Acquired medical liabilities (see Note 4 )</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>458,378</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Claims paid:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Current year</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(3,245,283)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(2,976)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Prior years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(90,367)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Total claims paid</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(3,335,650)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(2,976)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Risk pool settlement</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(384,869)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Accrual for net deficit from full risk capitation contracts</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>544,041</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>99,936</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="58%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="58%"> <div>Adjustments</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>(785,143)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="58%"> <div>Balance, end of period</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,260,549</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>552,561</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>285,625</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

CY2015Q1

us-gaap

Accounts Payable And Accrued Liabilities Current And Noncurrent

AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent

41245

USD

CY2014Q1

us-gaap

Accounts Payable Current And Noncurrent

AccountsPayableCurrentAndNoncurrent

819380

USD

CY2014Q3

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice

10.00

CY2015

us-gaap

Business Acquisitions Pro Forma Revenue

BusinessAcquisitionsProFormaRevenue

37036240

USD

CY2015

us-gaap

Business Acquisitions Pro Forma Net Income Loss

BusinessAcquisitionsProFormaNetIncomeLoss

-2244224

USD

CY2015

ameh

Business Acquisition Pro Forma Earnings Per Share Basic And Diluted

BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted

-0.46

Name	View Source	Status
0001144204-15-042438-index-headers.html	Edgar Link	pending
0001144204-15-042438-index.html	Edgar Link	pending
0001144204-15-042438.txt	Edgar Link	pending
0001144204-15-042438-xbrl.zip	Edgar Link	pending
ameh-20150331.xml	Edgar Link	completed
ameh-20150331.xsd	Edgar Link	pending
ameh-20150331_cal.xml	Edgar Link	unprocessable
ameh-20150331_def.xml	Edgar Link	unprocessable
ameh-20150331_lab.xml	Edgar Link	unprocessable
ameh-20150331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v413482_10k.htm	Edgar Link	pending
v413482_ex21-1.htm	Edgar Link	pending
v413482_ex23-1.htm	Edgar Link	pending
v413482_ex23-2.htm	Edgar Link	pending
v413482_ex31-1.htm	Edgar Link	pending
v413482_ex31-2.htm	Edgar Link	pending
v413482_ex32-1.htm	Edgar Link	pending
v413482_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ASTH
Astrana Health, Inc. Stock $asth

2015 Q3 Form 10-K Financial Statement

#000114420415042438 Filed on July 14, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ASTH Astrana Health, Inc. Stock $asth

2015 Q3 Form 10-K Financial Statement

#000114420415042438 Filed on July 14, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ASTH
Astrana Health, Inc. Stock $asth